<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Xenobiot</journal-id><journal-id journal-id-type="iso-abbrev">J Xenobiot</journal-id><journal-id journal-id-type="pmc-domain-id">3588</journal-id><journal-id journal-id-type="pmc-domain">jxenobio</journal-id><journal-id journal-id-type="publisher-id">jox</journal-id><journal-title-group><journal-title>Journal of Xenobiotics</journal-title></journal-title-group><issn pub-type="ppub">2039-4705</issn><issn pub-type="epub">2039-4713</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11503392</article-id><article-id pub-id-type="pmcid-ver">PMC11503392.1</article-id><article-id pub-id-type="pmcaid">11503392</article-id><article-id pub-id-type="pmcaiid">11503392</article-id><article-id pub-id-type="pmid">39449426</article-id><article-id pub-id-type="doi">10.3390/jox14040085</article-id><article-id pub-id-type="publisher-id">jox-14-00085</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Acute Quetiapine Intoxication: Relationship Between Ingested Dose, Serum Concentration and Clinical Presentation&#8212;Structured Literature Review and Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9470-971X</contrib-id><name name-style="western"><surname>Dobravc Verbi&#269;</surname><given-names initials="M">Matej</given-names></name><xref rid="af1-jox-14-00085" ref-type="aff">1</xref><xref rid="af2-jox-14-00085" ref-type="aff">2</xref><xref rid="c1-jox-14-00085" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3452-1499</contrib-id><name name-style="western"><surname>Grabnar</surname><given-names initials="I">Iztok</given-names></name><xref rid="af2-jox-14-00085" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4753-2747</contrib-id><name name-style="western"><surname>Eyer</surname><given-names initials="F">Florian</given-names></name><xref rid="af3-jox-14-00085" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8493-3638</contrib-id><name name-style="western"><surname>Brvar</surname><given-names initials="M">Miran</given-names></name><xref rid="af1-jox-14-00085" ref-type="aff">1</xref><xref rid="af4-jox-14-00085" ref-type="aff">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Esteves</surname><given-names initials="F">Francisco</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jox-14-00085"><label>1</label>Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; <email>miran.brvar@kclj.si</email></aff><aff id="af2-jox-14-00085"><label>2</label>The Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia; <email>iztok.grabnar@ffa.uni-lj.si</email></aff><aff id="af3-jox-14-00085"><label>3</label>Department of Clinical Toxicology, TUM University Hospital, Technical University of Munich, 81675 Munich, Germany; <email>florian.eyer@tum.de</email></aff><aff id="af4-jox-14-00085"><label>4</label>Centre for Clinical Physiology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia</aff><author-notes><corresp id="c1-jox-14-00085"><label>*</label>Correspondence: <email>matej.dobravcverbic@kclj.si</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>14</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">473537</issue-id><fpage>1570</fpage><lpage>1594</lpage><history><date date-type="received"><day>04</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>26</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-26 00:25:16.857"><day>26</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jox-14-00085.pdf"/><abstract><p>Over the past decade, quetiapine has become one of the most commonly used psychotropic drugs in acute intoxication events worldwide. A structured literature review and analysis were conducted to assess the relationship between the kinetic and dynamic profiles in acute quetiapine intoxication. The correlation between dose and peak serum concentration (c<sub>max</sub>) was determined using Pearson&#8217;s correlation coefficient. Binary logistic regression was used to evaluate dose and c<sub>max</sub> as predictors of the most common clinical events, signs and symptoms. One hundred and thirty-four cases of acute quetiapine ingestion were included in the analysis, with a median ingested dose of 10 g and a median c<sub>max</sub> of 4 mg/L. The typical half-life was estimated to be 16.5 h, significantly longer than at therapeutic doses. For the immediate-release formulation, a biphasic disposition could not be excluded. Dose and c<sub>max</sub> demonstrated a weak but significant correlation (r = 0.256; N = 63; <italic toggle="yes">p</italic> = 0.043). Central nervous system depression and tachycardia were the most common clinical signs. Higher doses and concentrations increased the risk of severe intoxication and were good predictors of intubation, tachycardia, hypotension, QT<sub>c</sub> prolongation and seizures, but not QRS prolongation, arrhythmia, heart block, hypokalaemia or acidosis. The thresholds for dose and c<sub>max</sub> that increased the risk for individual signs and symptoms varied widely. However, doses &gt; 3 g or c<sub>max</sub> &gt; 2 mg/L can be considered as alert levels that represent a high risk for severe clinical course of acute quetiapine intoxication.</p></abstract><kwd-group><kwd>intoxication</kwd><kwd>quetiapine</kwd><kwd>toxicokinetics</kwd><kwd>toxicodynamics</kwd></kwd-group><funding-group><award-group><funding-source>the Slovenian Research and Innovation Agency</funding-source><award-id>P3-0019</award-id><award-id>P1-0189</award-id></award-group><funding-statement>This research was funded by the Slovenian Research and Innovation Agency grant No. P3-0019 to M.B.; I.G acknowledges the financial support from the Slovenian Research and Innovation Agency (grant No. P1-0189).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jox-14-00085"><title>1. Introduction</title><p>Quetiapine (QTP) is a dibenzothiazepine antipsychotic drug approved for the treatment of schizophrenia, bipolar disorder and major depressive disorder [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B3-jox-14-00085" ref-type="bibr">3</xref>]. However, estimates from several Western countries have shown that 60&#8211;70% of patients receiving QTP use it for indications outside the registration [<xref rid="B4-jox-14-00085" ref-type="bibr">4</xref>,<xref rid="B5-jox-14-00085" ref-type="bibr">5</xref>,<xref rid="B6-jox-14-00085" ref-type="bibr">6</xref>,<xref rid="B7-jox-14-00085" ref-type="bibr">7</xref>,<xref rid="B8-jox-14-00085" ref-type="bibr">8</xref>,<xref rid="B9-jox-14-00085" ref-type="bibr">9</xref>]. In particular, low-dose QTP has demonstrated efficacy and tolerability in a broader range of psychiatric disorders and has become a common substitute for benzodiazepines in the treatment of anxiety and insomnia [<xref rid="B3-jox-14-00085" ref-type="bibr">3</xref>,<xref rid="B5-jox-14-00085" ref-type="bibr">5</xref>,<xref rid="B7-jox-14-00085" ref-type="bibr">7</xref>,<xref rid="B8-jox-14-00085" ref-type="bibr">8</xref>,<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>,<xref rid="B11-jox-14-00085" ref-type="bibr">11</xref>,<xref rid="B12-jox-14-00085" ref-type="bibr">12</xref>,<xref rid="B13-jox-14-00085" ref-type="bibr">13</xref>,<xref rid="B14-jox-14-00085" ref-type="bibr">14</xref>,<xref rid="B15-jox-14-00085" ref-type="bibr">15</xref>,<xref rid="B16-jox-14-00085" ref-type="bibr">16</xref>,<xref rid="B17-jox-14-00085" ref-type="bibr">17</xref>,<xref rid="B18-jox-14-00085" ref-type="bibr">18</xref>,<xref rid="B19-jox-14-00085" ref-type="bibr">19</xref>,<xref rid="B20-jox-14-00085" ref-type="bibr">20</xref>,<xref rid="B21-jox-14-00085" ref-type="bibr">21</xref>,<xref rid="B22-jox-14-00085" ref-type="bibr">22</xref>]. As patients treated with QTP frequently suffer from debilitating and chronic psychiatric conditions, intoxication events, including suicide attempts with QTP, are not uncommon [<xref rid="B23-jox-14-00085" ref-type="bibr">23</xref>]. Over the past decade, QTP has become one of the psychotropic drugs most commonly implicated in acute intoxication events worldwide [<xref rid="B17-jox-14-00085" ref-type="bibr">17</xref>,<xref rid="B18-jox-14-00085" ref-type="bibr">18</xref>,<xref rid="B24-jox-14-00085" ref-type="bibr">24</xref>,<xref rid="B25-jox-14-00085" ref-type="bibr">25</xref>].</p><p>The severity of QTP intoxication may be difficult to predict [<xref rid="B12-jox-14-00085" ref-type="bibr">12</xref>]. Reported toxicity varies widely across the dose range. Peak serum concentration may be a good predictor of QTP toxicity [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>] but is infrequently measured [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>]. The existing data from individual case reports and studies in this regard have been confounding [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B12-jox-14-00085" ref-type="bibr">12</xref>,<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>,<xref rid="B30-jox-14-00085" ref-type="bibr">30</xref>]. With the lack of clinical trials related to a toxicological setting [<xref rid="B31-jox-14-00085" ref-type="bibr">31</xref>], determining the relationship between dose, concentration and clinical picture can provide essential information in the management of intoxications.</p><p>This review article focuses on the relationship between the kinetic and dynamic profiles in acute intoxication with QTP. In the first part, the existing knowledge is described. In the second part, previously published cases are collected from the literature, and the joint data are statistically analysed to determine the relationship between the ingested QTP dose, serum concentrations and individual toxicodynamic parameters.</p></sec><sec id="sec2-jox-14-00085"><title>2. Review of the Existing Literature</title><sec id="sec2dot1-jox-14-00085"><title>2.1. Quetiapine in Therapeutic Use</title><sec id="sec2dot1dot1-jox-14-00085"><title>2.1.1. Pharmacokinetic Profile and Dose&#8211;Concentration Correlation in Therapeutic Use</title><p>QTP is therapeutically administered in single or multiple oral doses, ranging from 25 to 800 mg daily. It is available in immediate-release (IR) and extended-release (XR) oral dosage forms [<xref rid="B32-jox-14-00085" ref-type="bibr">32</xref>]. In the therapeutic dose range, QTP exhibits linear pharmacokinetics [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B34-jox-14-00085" ref-type="bibr">34</xref>,<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>,<xref rid="B36-jox-14-00085" ref-type="bibr">36</xref>,<xref rid="B37-jox-14-00085" ref-type="bibr">37</xref>,<xref rid="B38-jox-14-00085" ref-type="bibr">38</xref>]. <xref rid="jox-14-00085-t001" ref-type="table">Table 1</xref> presents the kinetic parameters for the IR and XR formulations in therapeutic and toxic dose ranges.</p><p>At therapeutic doses, the time to peak concentration (t<sub>max</sub>) with XR form is delayed by approximately 3 h, and serum concentration peak (c<sub>max</sub>) is attenuated [<xref rid="B19-jox-14-00085" ref-type="bibr">19</xref>]. Release occurs over 20 h [<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>]. A similar relative exposure is achieved with both forms in the therapeutic range [<xref rid="B41-jox-14-00085" ref-type="bibr">41</xref>,<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>]. The steady-state c<sub>max</sub> and area under curve (AUC) of 300 mg XR once daily and 150 mg IR twice daily are considered equivalent [<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>]. QTP population pharmacokinetic models were one compartmental with first-order absorption [<xref rid="B42-jox-14-00085" ref-type="bibr">42</xref>,<xref rid="B45-jox-14-00085" ref-type="bibr">45</xref>,<xref rid="B46-jox-14-00085" ref-type="bibr">46</xref>]. Interindividual variability of pharmacokinetic parameters was estimated to be 78% to 140% [<xref rid="B42-jox-14-00085" ref-type="bibr">42</xref>].</p><p>QTP is a CYP3A4 substrate and may interact with analgesic, anticonvulsant, antiarrhythmic and antiparkinsonian drugs [<xref rid="B17-jox-14-00085" ref-type="bibr">17</xref>]. Coadministration of ketoconazole, a potent CYP3A4 inhibitor, results in a 3&#8211;4-fold increase in QTP c<sub>max</sub>, whereas phenytoin and carbamazepine as CYP3A4 inducers cause a 5-fold increase in QTP metabolism and a similar decrease in steady-state c<sub>max</sub> [<xref rid="B34-jox-14-00085" ref-type="bibr">34</xref>,<xref rid="B57-jox-14-00085" ref-type="bibr">57</xref>,<xref rid="B59-jox-14-00085" ref-type="bibr">59</xref>].</p><p>In the &#171;Arbeitsgemeinschaft f&#252;r Neuropsychopharmakologie und Pharmakopsychiatrie&#187; (AGNP) consensus guidelines, the reference range for QTP serum/plasma concentrations are set at 0.1&#8211;0.5 mg/L [<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>,<xref rid="B60-jox-14-00085" ref-type="bibr">60</xref>,<xref rid="B61-jox-14-00085" ref-type="bibr">61</xref>,<xref rid="B62-jox-14-00085" ref-type="bibr">62</xref>]. However, the required concentrations vary for different mental conditions. QTP trough levels of 0.02&#8211;0.3 mg/L have been associated with efficacy [<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>], while concentrations of up to 1 mg/L have been described as therapeutic [<xref rid="B23-jox-14-00085" ref-type="bibr">23</xref>,<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B62-jox-14-00085" ref-type="bibr">62</xref>,<xref rid="B63-jox-14-00085" ref-type="bibr">63</xref>].</p><p>The relationship between QTP dose and concentration demonstrates large interindividual variability. In 62 patients treated with 37.5&#8211;1200 mg QTP daily, the concentration/dose (C/D) ratio varied 238-fold [<xref rid="B64-jox-14-00085" ref-type="bibr">64</xref>]. In a therapeutic drug monitoring (TDM) analysis of adult patients treated with 12.5&#8211;2600 mg QTP daily, C/D ratios ranged from 0.01 to 6.9 nmol/L/mg [<xref rid="B65-jox-14-00085" ref-type="bibr">65</xref>]. In certain subpopulations, the C/D correlation may be stronger. A linear relationship between QTP plasma levels and dose per kg body weight was found in 41 patients with schizophrenia, drug-induced psychosis or borderline personality disorder [<xref rid="B66-jox-14-00085" ref-type="bibr">66</xref>]. C/D correlation was strong in 12 elderly patients with selected psychotic disorders [<xref rid="B67-jox-14-00085" ref-type="bibr">67</xref>]. A weak positive linear C/D relationship was found in 180 children and adolescents with psychotic and mood disorders [<xref rid="B68-jox-14-00085" ref-type="bibr">68</xref>].</p></sec><sec id="sec2dot1dot2-jox-14-00085"><title>2.1.2. Clinical and Adverse Effects of Quetiapine</title><p>QTP acts via several pathways in the central nervous system (CNS). The desired effects and the adverse drug reaction (ADR) profile follow receptor binding affinity, which is largely dose-dependent [<xref rid="B14-jox-14-00085" ref-type="bibr">14</xref>]. Sedative effects at low doses are mainly mediated by histaminergic (H<sub>1</sub>) and adrenergic receptors [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B37-jox-14-00085" ref-type="bibr">37</xref>,<xref rid="B69-jox-14-00085" ref-type="bibr">69</xref>]. H<sub>1</sub> antagonism is associated with increased appetite and weight gain [<xref rid="B70-jox-14-00085" ref-type="bibr">70</xref>]. &#945;<sub>1</sub> blockade can cause orthostasis, hypotension and reflex tachycardia [<xref rid="B70-jox-14-00085" ref-type="bibr">70</xref>]. At higher doses (&gt;300 mg), the mood-stabilising and antipsychotic effects increase due to antagonistic effects on serotonin (5-HT<sub>2A</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2C</sub>) and dopamine (D<sub>1</sub>, D<sub>2</sub>) receptors [<xref rid="B14-jox-14-00085" ref-type="bibr">14</xref>]. Extrapyramidal symptoms do not normally occur at therapeutic doses due to lower affinity for D<sub>2</sub> receptors [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B61-jox-14-00085" ref-type="bibr">61</xref>]. Antimuscarinic ADRs, e.g., dry mouth or constipation, can be observed at higher doses [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>]. Less common ADRs include dyspepsia, hyperprolactinaemia and sexual dysfunction [<xref rid="B39-jox-14-00085" ref-type="bibr">39</xref>,<xref rid="B62-jox-14-00085" ref-type="bibr">62</xref>,<xref rid="B68-jox-14-00085" ref-type="bibr">68</xref>,<xref rid="B71-jox-14-00085" ref-type="bibr">71</xref>,<xref rid="B72-jox-14-00085" ref-type="bibr">72</xref>,<xref rid="B73-jox-14-00085" ref-type="bibr">73</xref>,<xref rid="B74-jox-14-00085" ref-type="bibr">74</xref>,<xref rid="B75-jox-14-00085" ref-type="bibr">75</xref>]. As with other antipsychotics, QT<sub>c</sub> prolongation is likely to be dose-related [<xref rid="B76-jox-14-00085" ref-type="bibr">76</xref>,<xref rid="B77-jox-14-00085" ref-type="bibr">77</xref>,<xref rid="B78-jox-14-00085" ref-type="bibr">78</xref>,<xref rid="B79-jox-14-00085" ref-type="bibr">79</xref>]. Other rare but serious ADRs include neuroleptic malignant syndrome (NMS), hepatotoxicity, myocarditis and blood dyscrasia [<xref rid="B80-jox-14-00085" ref-type="bibr">80</xref>,<xref rid="B81-jox-14-00085" ref-type="bibr">81</xref>,<xref rid="B82-jox-14-00085" ref-type="bibr">82</xref>,<xref rid="B83-jox-14-00085" ref-type="bibr">83</xref>,<xref rid="B84-jox-14-00085" ref-type="bibr">84</xref>,<xref rid="B85-jox-14-00085" ref-type="bibr">85</xref>,<xref rid="B86-jox-14-00085" ref-type="bibr">86</xref>,<xref rid="B87-jox-14-00085" ref-type="bibr">87</xref>,<xref rid="B88-jox-14-00085" ref-type="bibr">88</xref>]. The XR form is generally better tolerated and causes less drowsiness in the initial hours post-ingestion. However, its effects may last longer [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>,<xref rid="B39-jox-14-00085" ref-type="bibr">39</xref>].</p><p>Certain ADRs, e.g., anticholinergic delirium, urinary retention, sinus tachycardia and increased intraocular pressure, can be partly attributed to one of the two active metabolites, norquetiapine (N-desalkylquetiapine, norQTP) [<xref rid="B70-jox-14-00085" ref-type="bibr">70</xref>,<xref rid="B89-jox-14-00085" ref-type="bibr">89</xref>,<xref rid="B90-jox-14-00085" ref-type="bibr">90</xref>,<xref rid="B91-jox-14-00085" ref-type="bibr">91</xref>].</p></sec><sec id="sec2dot1dot3-jox-14-00085"><title>2.1.3. Relationship Between Dose or Concentration and Clinical Response</title><p>Data on the relationship between QTP dose or plasma concentration and clinical response are limited [<xref rid="B61-jox-14-00085" ref-type="bibr">61</xref>]. Most studies have failed to demonstrate a significant correlation [<xref rid="B46-jox-14-00085" ref-type="bibr">46</xref>,<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>,<xref rid="B68-jox-14-00085" ref-type="bibr">68</xref>,<xref rid="B73-jox-14-00085" ref-type="bibr">73</xref>,<xref rid="B92-jox-14-00085" ref-type="bibr">92</xref>,<xref rid="B93-jox-14-00085" ref-type="bibr">93</xref>,<xref rid="B94-jox-14-00085" ref-type="bibr">94</xref>,<xref rid="B95-jox-14-00085" ref-type="bibr">95</xref>,<xref rid="B96-jox-14-00085" ref-type="bibr">96</xref>]. In Chinese patients with bipolar disorder, QTP serum concentrations but not daily doses were strongly correlated with clinical outcomes [<xref rid="B62-jox-14-00085" ref-type="bibr">62</xref>]. In 41 patients with schizophrenia, drug-induced psychosis or borderline personality disorder, patient improvement correlated with plasma levels and dose/kg body weight within each diagnostic category but not between categories [<xref rid="B66-jox-14-00085" ref-type="bibr">66</xref>].</p></sec></sec><sec id="sec2dot2-jox-14-00085"><title>2.2. Quetiapine in Acute Intoxication</title><sec id="sec2dot2dot1-jox-14-00085"><title>2.2.1. Acute Toxicity Dose and Concentration Range</title><p>A single dose of QTP that presents an acute intoxication is not defined, and there is a large overlap with therapeutic doses. For atypical antipsychotics, an expert consensus panel suggested that ingestion of &lt;5 times the initial adult single dose (i.e., &lt;125 mg for QTP) presented a relatively low risk of severe intoxication in na&#239;ve patients &#8805; 12 years old. For patients receiving chronic therapy with QTP, the suggested threshold was five times their personal single dose [<xref rid="B97-jox-14-00085" ref-type="bibr">97</xref>]. In a retrospective analysis, QTP intoxication was defined as &#8220;a one-time ingestion of more than 400 mg of QTP&#8221; [<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>]. On the other hand, in studies assessing the correlation between QTP plasma concentration and therapeutic response, daily doses of up to 1800 mg were used [<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>,<xref rid="B98-jox-14-00085" ref-type="bibr">98</xref>]. In a small open-label study, doses of up to 1600 mg daily were well tolerated during a four-week acute phase, and doses up to 1000 mg were used and tolerated in the maintenance phase [<xref rid="B99-jox-14-00085" ref-type="bibr">99</xref>].</p><p>In the AGNP guidelines, QTP plasma concentration &gt; 1.0 mg/L is considered toxic. This threshold was calculated by doubling the upper limit of therapeutic concentration [<xref rid="B21-jox-14-00085" ref-type="bibr">21</xref>], which frequently defines the laboratory alert level for antipsychotics [<xref rid="B100-jox-14-00085" ref-type="bibr">100</xref>]. Based on case reports, a higher toxicity threshold of 1.8 mg/L has been proposed. Concentrations &#8805; 1.9 mg/L have been reported as potentially comatose-fatal [<xref rid="B101-jox-14-00085" ref-type="bibr">101</xref>]. In postmortem analyses, blood levels &gt; 1 mg/L generally indicated QTP as a contributing factor to death [<xref rid="B69-jox-14-00085" ref-type="bibr">69</xref>].</p></sec><sec id="sec2dot2dot2-jox-14-00085"><title>2.2.2. Toxicokinetic Profile</title><p>The available toxicokinetic data for QTP are based on cohort studies and case reports (<xref rid="jox-14-00085-t001" ref-type="table">Table 1</xref>). The bioavailability in acute intoxication is lower than at therapeutic doses [<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>]. In part, this may be due to the anticholinergic effects of QTP [<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>]. The use of decontamination procedures, e.g., activated charcoal, when administered promptly, may significantly reduce the amount absorbed [<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>]. Gastric emptying may be prolonged due to acute stress associated with severe poisoning and coingested drugs [<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>,<xref rid="B100-jox-14-00085" ref-type="bibr">100</xref>,<xref rid="B102-jox-14-00085" ref-type="bibr">102</xref>]. In several cases of QTP IR ingestion, the t<sub>max</sub> was &gt;12 h [<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>]. The reported half-life (t<sub>1/2</sub>) has a wide range. Both linear and non-linear elimination have been suggested [<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>,<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>]. Clinical studies conducted during product registration in which therapeutic doses were analysed may underestimate t<sub>1/2</sub> at toxic doses [<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>].</p><p>Pharmacobezoars may contribute to delayed absorption and t<sub>max</sub>, particularly with XR formulations, but have also been found in rare cases with IR formulations at doses &gt; 2.5 g [<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>,<xref rid="B100-jox-14-00085" ref-type="bibr">100</xref>,<xref rid="B103-jox-14-00085" ref-type="bibr">103</xref>,<xref rid="B104-jox-14-00085" ref-type="bibr">104</xref>,<xref rid="B105-jox-14-00085" ref-type="bibr">105</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>]. In an in vitro study of QTP XR, the bezoars remained stable for more than 4 h, and the drug release was reduced by 53% [<xref rid="B107-jox-14-00085" ref-type="bibr">107</xref>]. In addition to the delayed serum concentration increase, bezoars pose a risk of additional complications, e.g., gastric or intestinal obstruction [<xref rid="B107-jox-14-00085" ref-type="bibr">107</xref>].</p></sec><sec id="sec2dot2dot3-jox-14-00085"><title>2.2.3. Toxicodynamic Profile</title><p>QTP demonstrates a variable range of toxicity [<xref rid="B23-jox-14-00085" ref-type="bibr">23</xref>,<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>]. Intoxication causes symptoms such as CNS depression, lethargy, confusion, drowsiness, tachycardia, hypotension, respiratory depression, anticholinergic symptoms and ataxia [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>,<xref rid="B12-jox-14-00085" ref-type="bibr">12</xref>,<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>,<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>,<xref rid="B97-jox-14-00085" ref-type="bibr">97</xref>,<xref rid="B108-jox-14-00085" ref-type="bibr">108</xref>,<xref rid="B109-jox-14-00085" ref-type="bibr">109</xref>,<xref rid="B110-jox-14-00085" ref-type="bibr">110</xref>,<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>,<xref rid="B112-jox-14-00085" ref-type="bibr">112</xref>,<xref rid="B113-jox-14-00085" ref-type="bibr">113</xref>]. Orthostatic hypotension, miosis, agitation and delirium are commonly encountered [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>,<xref rid="B108-jox-14-00085" ref-type="bibr">108</xref>,<xref rid="B114-jox-14-00085" ref-type="bibr">114</xref>]. Hyperglycaemia and hypokalaemia occur less frequently [<xref rid="B52-jox-14-00085" ref-type="bibr">52</xref>]. Severe toxicity may be more common than with other atypical antipsychotics, occurring in about one-sixth of patients [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>,<xref rid="B115-jox-14-00085" ref-type="bibr">115</xref>]. Clinical signs include seizures, status epilepticus, rhabdomyolysis, respiratory depression, hypotension, coma and death [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>,<xref rid="B116-jox-14-00085" ref-type="bibr">116</xref>,<xref rid="B117-jox-14-00085" ref-type="bibr">117</xref>,<xref rid="B118-jox-14-00085" ref-type="bibr">118</xref>,<xref rid="B119-jox-14-00085" ref-type="bibr">119</xref>]. In a review of 945 cases of QTP overdose, 388 cases (41.1%) required admission to the intensive care unit (ICU) [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>]. Coma was reported in 10% of QTP intoxication cases [<xref rid="B60-jox-14-00085" ref-type="bibr">60</xref>]. Fatal outcomes are rare, and there are known cases of patients surviving a very high overdose [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>,<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>]. On the other hand, deaths have been reported even after therapeutic doses [<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>]. The mortality risk is higher than with other atypical antipsychotics [<xref rid="B120-jox-14-00085" ref-type="bibr">120</xref>,<xref rid="B121-jox-14-00085" ref-type="bibr">121</xref>]. In acute poisoning, complications such as aspiration pneumonia can contribute to death [<xref rid="B60-jox-14-00085" ref-type="bibr">60</xref>]. An Australian analysis estimated a 1.2% death rate directly attributable to QTP overdose in cases with QTP detected in postmortem blood [<xref rid="B115-jox-14-00085" ref-type="bibr">115</xref>,<xref rid="B122-jox-14-00085" ref-type="bibr">122</xref>].</p><p>Sinus tachycardia occurs in the majority of patients after severe intoxication [<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>,<xref rid="B123-jox-14-00085" ref-type="bibr">123</xref>]. It results from antimuscarinic activity and may also be a reflex to &#945;<sub>1</sub>-induced vasodilation and hypotension [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B52-jox-14-00085" ref-type="bibr">52</xref>,<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>,<xref rid="B103-jox-14-00085" ref-type="bibr">103</xref>,<xref rid="B124-jox-14-00085" ref-type="bibr">124</xref>]. Hypotension is more common than with most other antipsychotics and occurs in up to 40% of patients [<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>,<xref rid="B115-jox-14-00085" ref-type="bibr">115</xref>,<xref rid="B123-jox-14-00085" ref-type="bibr">123</xref>]. In most cases, it can be resolved with intravenous fluid replacement. Profound hypotension resistant to volume resuscitation is rare [<xref rid="B125-jox-14-00085" ref-type="bibr">125</xref>]. CNS and respiratory depression are related to the antagonistic action on 5-HT and dopamine receptors [<xref rid="B126-jox-14-00085" ref-type="bibr">126</xref>,<xref rid="B127-jox-14-00085" ref-type="bibr">127</xref>]. The antimuscarinic effects can cause transient sedation [<xref rid="B128-jox-14-00085" ref-type="bibr">128</xref>]. Histaminergic sedation is predominant in lower dose ranges [<xref rid="B14-jox-14-00085" ref-type="bibr">14</xref>].</p><p>There are several published reports of QT<sub>c</sub> interval prolongation [<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B52-jox-14-00085" ref-type="bibr">52</xref>,<xref rid="B128-jox-14-00085" ref-type="bibr">128</xref>], but its clinical significance remains controversial [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B129-jox-14-00085" ref-type="bibr">129</xref>,<xref rid="B130-jox-14-00085" ref-type="bibr">130</xref>]. In a US multicentre cohort study, QTP caused severe QT prolongation, defined as QT<sub>c</sub> &#8805; 500 ms using Bazett&#8217;s correction, in 96 of 471 intoxication cases [<xref rid="B131-jox-14-00085" ref-type="bibr">131</xref>]. In a case series of QTP poisoning published by Balit et al., the uncorrected QT interval was not altered despite the QT<sub>c</sub> increase. The authors argued that the prolonged QT<sub>c</sub> interval resulted from overcorrection by Bazett&#8217;s formula due to tachycardia rather than from intrinsic cardiac toxicity [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>]. Cardiac arrhythmias are very rare [<xref rid="B107-jox-14-00085" ref-type="bibr">107</xref>,<xref rid="B132-jox-14-00085" ref-type="bibr">132</xref>,<xref rid="B133-jox-14-00085" ref-type="bibr">133</xref>]. Ngo et al. reported two cases of ventricular tachycardia without torsade de pointes [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>]. A single case report describes Brugada syndrome following QTP intoxication [<xref rid="B134-jox-14-00085" ref-type="bibr">134</xref>]. Widened QRS complexes can be a sign of immediate circulatory collapse [<xref rid="B135-jox-14-00085" ref-type="bibr">135</xref>]. They have been associated with an increased risk of seizures and ventricular dysrhythmia [<xref rid="B136-jox-14-00085" ref-type="bibr">136</xref>]. Heart block, possibly related to hypokalaemia, is not uncommon [<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B137-jox-14-00085" ref-type="bibr">137</xref>].</p><p>Seizures can be induced by antagonism on dopamine (D<sub>2</sub>), histamine or adrenergic receptors, as well as hypoxia [<xref rid="B138-jox-14-00085" ref-type="bibr">138</xref>]. They occur infrequently, typically within 4&#8211;8 h post-ingestion, and are self-limiting in the majority of cases [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>,<xref rid="B138-jox-14-00085" ref-type="bibr">138</xref>]. In a retrospective 5-year case series, the incidence of seizures in acute QTP intoxication events was 2% [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>]. Late-onset seizures (&#8805;24 h post-ingestion) have been described after ingestion of QTP at doses of 4 g to 30 g [<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>,<xref rid="B139-jox-14-00085" ref-type="bibr">139</xref>,<xref rid="B140-jox-14-00085" ref-type="bibr">140</xref>]. The relationship between severity and QTP serum concentration has not been clarified, and seizures have been reported at therapeutic doses [<xref rid="B141-jox-14-00085" ref-type="bibr">141</xref>,<xref rid="B142-jox-14-00085" ref-type="bibr">142</xref>,<xref rid="B143-jox-14-00085" ref-type="bibr">143</xref>,<xref rid="B144-jox-14-00085" ref-type="bibr">144</xref>]. Similarly, myoclonus has been reported as a leading symptom of QTP intoxication [<xref rid="B145-jox-14-00085" ref-type="bibr">145</xref>] but may also occur at higher therapeutic doses administered therapeutically [<xref rid="B146-jox-14-00085" ref-type="bibr">146</xref>,<xref rid="B147-jox-14-00085" ref-type="bibr">147</xref>].</p><p>Agitation has been reported at higher therapeutic doses [<xref rid="B148-jox-14-00085" ref-type="bibr">148</xref>]. In acute intoxication, it may follow initial drowsiness and lethargy after several hours [<xref rid="B149-jox-14-00085" ref-type="bibr">149</xref>]. Anticholinergic delirium may also occur at a late stage after a period of decreased consciousness and persist for several days, possibly due to delayed QTP absorption and/or elimination [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B55-jox-14-00085" ref-type="bibr">55</xref>,<xref rid="B91-jox-14-00085" ref-type="bibr">91</xref>]. Coingested drugs, clinical interventions (e.g., intubation), somatic complications and underlying psychiatric disorders may contribute to delirium [<xref rid="B91-jox-14-00085" ref-type="bibr">91</xref>,<xref rid="B150-jox-14-00085" ref-type="bibr">150</xref>,<xref rid="B151-jox-14-00085" ref-type="bibr">151</xref>].</p><p>Rhabdomyolysis has been described after a period of immobility of at least 14 h [<xref rid="B152-jox-14-00085" ref-type="bibr">152</xref>,<xref rid="B153-jox-14-00085" ref-type="bibr">153</xref>,<xref rid="B154-jox-14-00085" ref-type="bibr">154</xref>]. However, in the case of a 48-year-old man ingesting 12 g of QTP, rhabdomyolysis may have occurred due to a direct toxic effect of QTP, as no muscle wasting or pain was present [<xref rid="B152-jox-14-00085" ref-type="bibr">152</xref>]. NMS has been rarely reported and is considered idiosyncratic. It has occurred even at therapeutic doses as low as 12.5 mg daily [<xref rid="B155-jox-14-00085" ref-type="bibr">155</xref>,<xref rid="B156-jox-14-00085" ref-type="bibr">156</xref>,<xref rid="B157-jox-14-00085" ref-type="bibr">157</xref>,<xref rid="B158-jox-14-00085" ref-type="bibr">158</xref>,<xref rid="B159-jox-14-00085" ref-type="bibr">159</xref>,<xref rid="B160-jox-14-00085" ref-type="bibr">160</xref>,<xref rid="B161-jox-14-00085" ref-type="bibr">161</xref>]. It is characterised by fever, rigidity, autonomic instability and altered mental status. Elevated creatine kinase levels and leucocytosis are common. Without early recognition, it can lead to rhabdomyolysis, respiratory failure, acute kidney injury, seizures and death [<xref rid="B162-jox-14-00085" ref-type="bibr">162</xref>]. Following intoxication with the XR form, delayed toxicity with prolonged coma, rhabdomyolysis and aspiration pneumonia are more likely [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>,<xref rid="B32-jox-14-00085" ref-type="bibr">32</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>].</p><p>Treatment of acute QTP intoxication is symptomatic, and patients should be monitored [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>,<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>]. There is no specific antidote. The use of activated charcoal within 6 h post-ingestion reduces the absorption of QTP by 35% and shortens the apparent t<sub>1/2</sub> [<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>,<xref rid="B163-jox-14-00085" ref-type="bibr">163</xref>]. Gastric lavage may be considered for severe intoxications, ideally within 1 h post-ingestion [<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>]. Whole bowel irrigation has also been used [<xref rid="B149-jox-14-00085" ref-type="bibr">149</xref>]. During gastric lavage, a temporary increase in serum concentrations may occur [<xref rid="B164-jox-14-00085" ref-type="bibr">164</xref>]. QTP is not dialysable [<xref rid="B85-jox-14-00085" ref-type="bibr">85</xref>,<xref rid="B165-jox-14-00085" ref-type="bibr">165</xref>].</p><p>All patients experiencing symptoms beyond mild drowsiness should be referred to the Emergency Department, regardless of the ingested dose [<xref rid="B97-jox-14-00085" ref-type="bibr">97</xref>]. With an ingested dose &lt; 3 g and a Glasgow Coma Scale (GCS) score of 15 for 4 h post-ingestion, patients may be discharged to a psychiatric unit [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>]. The expected time of onset and peak of toxicity symptoms is within 6 h post-ingestion for the IR formulation [<xref rid="B97-jox-14-00085" ref-type="bibr">97</xref>]. For the XR formulation, the initial assessment of vital signs and mental status may not predict the severity of intoxication as the peak toxicity takes longer to develop [<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>]. If no sedation or tachycardia occurs within 12 h after an overdose with the XR formulation, severe intoxication can be excluded [<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>].</p></sec><sec id="sec2dot2dot4-jox-14-00085"><title>2.2.4. Relationship Between Dose or Concentration and Clinical Presentation in Quetiapine Intoxication</title><p>While the clinical signs and symptoms vary across the QTP dose range, c<sub>max</sub> may be a good predictor of toxicity [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>]. However, despite its therapeutic implications, plasma concentration is not commonly measured in toxicology, and obtaining a measurement at t<sub>max</sub> is challenging [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>]. An unreliable medical history, coingested drugs and the use of decontamination procedures can complicate the correlation assessment [<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>]. Therefore, dose, serum concentration and clinical presentation generally demonstrated a poor correlation [<xref rid="B12-jox-14-00085" ref-type="bibr">12</xref>,<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>,<xref rid="B30-jox-14-00085" ref-type="bibr">30</xref>]. However, in a retrospective analysis of 18 cases, QTP dose correlated with both c<sub>max</sub> and the severity of the outcome [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>]. In a cohort study of 286 QTP intoxication events, there was a modest correlation between dose and minimum blood pressure, and dose influenced the probability of intubation [<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>].</p><p>In postmortem analyses, whole blood concentrations may be more informative than serum concentrations [<xref rid="B166-jox-14-00085" ref-type="bibr">166</xref>]. The concentration ratio between whole blood and serum exceeded 1 at concentrations &gt; 2.5 mg/L [<xref rid="B166-jox-14-00085" ref-type="bibr">166</xref>], in contrast to therapeutic doses with a ratio of ~0.7 [<xref rid="B167-jox-14-00085" ref-type="bibr">167</xref>,<xref rid="B168-jox-14-00085" ref-type="bibr">168</xref>]. QTP is likely to undergo a significant postmortem redistribution from striated muscle, connective and adipose tissue [<xref rid="B21-jox-14-00085" ref-type="bibr">21</xref>]. Drug diffusion from bezoars in the gastrointestinal tract to adjacent tissues may occur following ingestion of large quantities [<xref rid="B21-jox-14-00085" ref-type="bibr">21</xref>]. In fatal QTP monointoxications, postmortem whole blood concentrations were above 7.2 mg/L [<xref rid="B47-jox-14-00085" ref-type="bibr">47</xref>,<xref rid="B166-jox-14-00085" ref-type="bibr">166</xref>,<xref rid="B169-jox-14-00085" ref-type="bibr">169</xref>]. In a study of 21 fatal cases, the authors reported the (central and peripheral) blood concentrations &lt; 1 mg/L as &#8220;therapeutic&#8221;, i.e., not related to death, and concentrations &gt; 1 mg/L as &#8220;above therapeutic&#8221; and death-related [<xref rid="B53-jox-14-00085" ref-type="bibr">53</xref>]. Higher postmortem blood concentrations, reaching up to 170 mg/L, were found in heart or central body cavity blood samples, probably due to a higher susceptibility for postmortem redistribution [<xref rid="B21-jox-14-00085" ref-type="bibr">21</xref>,<xref rid="B47-jox-14-00085" ref-type="bibr">47</xref>,<xref rid="B169-jox-14-00085" ref-type="bibr">169</xref>,<xref rid="B170-jox-14-00085" ref-type="bibr">170</xref>,<xref rid="B171-jox-14-00085" ref-type="bibr">171</xref>,<xref rid="B172-jox-14-00085" ref-type="bibr">172</xref>].</p></sec></sec></sec><sec id="sec3-jox-14-00085"><title>3. Analysis of Published Cases of Acute Quetiapine Intoxication</title><p>The aim of the analysis was to investigate the relationship between the ingested QTP dose, serum concentrations and individual toxicodynamic parameters with the joint data of published cases from the literature. While the clinical signs and symptoms of QTP intoxication have been well described, it remains unclear how specific parameters correlate with the ingested dose and concentration. Therefore, dose and concentration ranges for each dynamic parameter were investigated. Potential thresholds that represent an increased risk for the occurrence of individual signs and symptoms were determined.</p><sec id="sec3dot1-jox-14-00085"><title>3.1. Methods</title><sec id="sec3dot1dot1-jox-14-00085"><title>3.1.1. Literature Search and Inclusion/Exclusion Criteria</title><p>A literature search was conducted for relevant sources on QTP poisoning in the PubMed<sup>&#174;</sup> and EBSCO databases (including the Science Citation Index expanded). The search string was any combination of the words &#8220;quetiapine&#8221; or &#8220;Seroquel&#8221; and &#8220;poisoning&#8221;, &#8220;overdose&#8221; or &#8220;intoxication&#8221;. In the second phase, the references and the citing literature (if available on the website) were analysed. Book chapters, preclinical studies and in vitro studies were not analysed.</p><p>Cases of QTP intoxication in patients &#8805; 12 years old were included if the ingested dose and/or serum/plasma concentration of QTP were reported, along with a description of the clinical presentation. Cases with coingested agents were included if QTP was described as relevant to the clinical course. Cases of ADRs and drug interactions with therapeutic doses of QTP were excluded. Doses representing acute intoxication were the ingestions of &gt;5 times the initial adult single dose of QTP in na&#239;ve patients [<xref rid="B97-jox-14-00085" ref-type="bibr">97</xref>] or doses exceeding the approved therapeutic range, i.e., &gt;800 mg, in patients with regularly prescribed QTP [<xref rid="B173-jox-14-00085" ref-type="bibr">173</xref>].</p><p>Postmortem cases were included if any information on the clinical picture before death was available, together with the postmortem QTP concentration or the ingested dose. Only concentrations from peripheral blood samples were captured. Heart or cavity blood concentrations were not included as values may have been exaggerated due to postmortem redistribution [<xref rid="B69-jox-14-00085" ref-type="bibr">69</xref>,<xref rid="B171-jox-14-00085" ref-type="bibr">171</xref>,<xref rid="B174-jox-14-00085" ref-type="bibr">174</xref>].</p></sec><sec id="sec3dot1dot2-jox-14-00085"><title>3.1.2. Data Gathering and Statistical Analysis</title><p>The following data were extracted from the references: patient demographics (age, sex), details of QTP ingestion (amount ingested [mg], IR/XR form), QTP serum/plasma concentrations [mg/L], time from QTP ingestion and/or time from hospital admission to sampling [h], use of clinically relevant coingestants, treatment strategies and interventions (decontamination procedures, intubation, use of vasopressors, specific therapies), length of hospital stay [days], ICU admission, length of ICU stay [days], clinical events, signs and symptoms (lowest GCS score, tachycardia [heart rate &#8805; 100 beats per minute], hypotension [blood pressure &lt; 90/60 mm Hg, or &lt;100/50 mm Hg, or explicitly stated], QT<sub>c</sub> prolongation [QT<sub>c</sub> &gt; 480 ms, or &gt;55 ms above baseline, or explicitly stated QT or QT<sub>c</sub> prolongation], QRS prolongation [QRS &gt; 100 ms], arrhythmia, heart block, seizures, agitation, delirium, acidosis [serum pH &lt; 7.34], rhabdomyolysis [creatine kinase levels &gt; 1000 U/L], hypokalaemia [serum potassium level &lt; 3.5 mmol/L, or explicitly stated], hyperglycaemia [serum glucose level &#8805; 9 mmol/L]. Based on the lowest GCS score, cases were categorised into four grades according to the severity of intoxication: Grade 1: death; Grade 2: GCS = 3&#8211;8; Grade 3: GCS = 9&#8211;14; Grade 4: GCS = 15. If the GCS score was not explicitly stated, a three-member panel reviewed the case to determine whether the GCS grade (1&#8211;4) could be estimated from the clinical description.</p><p>Coingestants, considered clinically relevant, were all drugs taken in the context of acute intoxication affecting CNS, i.e., drugs of abuse, ethanol, drugs of the Anatomical Therapeutic Chemical Classification Group N (nervous system drugs), baclofen or diphenhydramine. Other clinically relevant coingestants were drugs with suspected clinically relevant kinetic interaction with QTP, e.g., potent CYP3A4 inhibitors.</p><p>Cases with reported ingested QTP dose and concentration, together with the estimated time from ingestion to sampling, were included in the concentration&#8211;time analysis. All concentration time points were dose normalised to 10 g of QTP. Time points &lt; 5 h post-ingestion for the XR QTP formulation were excluded from the t<sub>1/2</sub> estimation.</p><p>Pearson&#8217;s correlation coefficient was used to determine the correlation between QTP dose and c<sub>max</sub>. Binary logistic regression was used to evaluate QTP dose and c<sub>max</sub> as continuous predictor variables for individual toxicodynamic parameters (clinical events, signs and symptoms, and treatment strategies). For each parameter, cases were divided into two separate groups, the &#8220;event&#8221; group and the &#8220;no event&#8221; group. Logistic regression was performed for the parameters with at least 15 cases in the &#8220;event&#8221; group with reported QTP dose or concentration. The case distribution for each dynamic parameter was reviewed. Based on the distribution figures, additional logistic regression models with dose or concentration as categorical variables were created where appropriate. Pearson&#8217;s chi-square test was used to test the association between tachycardia and QT<sub>c</sub> prolongation, and Fisher&#8217;s exact test was used to test the association between QT<sub>c</sub> prolongation and arrhythmia. For all tests, a <italic toggle="yes">p</italic>-value &lt; 0.05 was the threshold for statistical significance.</p><p>Data analyses were performed in Microsoft Excel 2016 (descriptive statistics, dose-normalised concentration&#8211;time figures) and IBM SPSS Statistics 25 (distribution figures, logistic regression and other statistical tests).</p></sec></sec><sec id="sec3dot2-jox-14-00085"><title>3.2. Results and Discussion</title><p>The literature search, conducted on 11 March 2024, yielded 5437 results in the EBSCO database and 508 results in PubMed. Relevant case reports, case series, clinical studies, review articles, conference abstracts or annual Poison Control Centre reports were extracted. A total of 444 QTP intoxication cases were closely reviewed. Finally, 63 cases were included in the dose&#8211;concentration correlation assessment, 58 cases in the dose-normalised concentration&#8211;time figures, and 134 cases in the toxicokinetic&#8211;toxicodynamic correlation analysis, which were collected from 68 case reports, 16 case series, two cohort studies and six annual Poison Control Centre reports [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>,<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B12-jox-14-00085" ref-type="bibr">12</xref>,<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>,<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>,<xref rid="B49-jox-14-00085" ref-type="bibr">49</xref>,<xref rid="B52-jox-14-00085" ref-type="bibr">52</xref>,<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>,<xref rid="B55-jox-14-00085" ref-type="bibr">55</xref>,<xref rid="B56-jox-14-00085" ref-type="bibr">56</xref>,<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>,<xref rid="B71-jox-14-00085" ref-type="bibr">71</xref>,<xref rid="B72-jox-14-00085" ref-type="bibr">72</xref>,<xref rid="B85-jox-14-00085" ref-type="bibr">85</xref>,<xref rid="B103-jox-14-00085" ref-type="bibr">103</xref>,<xref rid="B104-jox-14-00085" ref-type="bibr">104</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>,<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>,<xref rid="B114-jox-14-00085" ref-type="bibr">114</xref>,<xref rid="B116-jox-14-00085" ref-type="bibr">116</xref>,<xref rid="B125-jox-14-00085" ref-type="bibr">125</xref>,<xref rid="B126-jox-14-00085" ref-type="bibr">126</xref>,<xref rid="B128-jox-14-00085" ref-type="bibr">128</xref>,<xref rid="B137-jox-14-00085" ref-type="bibr">137</xref>,<xref rid="B138-jox-14-00085" ref-type="bibr">138</xref>,<xref rid="B139-jox-14-00085" ref-type="bibr">139</xref>,<xref rid="B141-jox-14-00085" ref-type="bibr">141</xref>,<xref rid="B144-jox-14-00085" ref-type="bibr">144</xref>,<xref rid="B150-jox-14-00085" ref-type="bibr">150</xref>,<xref rid="B152-jox-14-00085" ref-type="bibr">152</xref>,<xref rid="B153-jox-14-00085" ref-type="bibr">153</xref>,<xref rid="B154-jox-14-00085" ref-type="bibr">154</xref>,<xref rid="B157-jox-14-00085" ref-type="bibr">157</xref>,<xref rid="B163-jox-14-00085" ref-type="bibr">163</xref>,<xref rid="B164-jox-14-00085" ref-type="bibr">164</xref>,<xref rid="B175-jox-14-00085" ref-type="bibr">175</xref>,<xref rid="B176-jox-14-00085" ref-type="bibr">176</xref>,<xref rid="B177-jox-14-00085" ref-type="bibr">177</xref>,<xref rid="B178-jox-14-00085" ref-type="bibr">178</xref>,<xref rid="B179-jox-14-00085" ref-type="bibr">179</xref>,<xref rid="B180-jox-14-00085" ref-type="bibr">180</xref>,<xref rid="B181-jox-14-00085" ref-type="bibr">181</xref>,<xref rid="B182-jox-14-00085" ref-type="bibr">182</xref>,<xref rid="B183-jox-14-00085" ref-type="bibr">183</xref>,<xref rid="B184-jox-14-00085" ref-type="bibr">184</xref>,<xref rid="B185-jox-14-00085" ref-type="bibr">185</xref>,<xref rid="B186-jox-14-00085" ref-type="bibr">186</xref>,<xref rid="B187-jox-14-00085" ref-type="bibr">187</xref>,<xref rid="B188-jox-14-00085" ref-type="bibr">188</xref>,<xref rid="B189-jox-14-00085" ref-type="bibr">189</xref>,<xref rid="B190-jox-14-00085" ref-type="bibr">190</xref>,<xref rid="B191-jox-14-00085" ref-type="bibr">191</xref>,<xref rid="B192-jox-14-00085" ref-type="bibr">192</xref>,<xref rid="B193-jox-14-00085" ref-type="bibr">193</xref>,<xref rid="B194-jox-14-00085" ref-type="bibr">194</xref>,<xref rid="B195-jox-14-00085" ref-type="bibr">195</xref>,<xref rid="B196-jox-14-00085" ref-type="bibr">196</xref>,<xref rid="B197-jox-14-00085" ref-type="bibr">197</xref>,<xref rid="B198-jox-14-00085" ref-type="bibr">198</xref>,<xref rid="B199-jox-14-00085" ref-type="bibr">199</xref>,<xref rid="B200-jox-14-00085" ref-type="bibr">200</xref>,<xref rid="B201-jox-14-00085" ref-type="bibr">201</xref>,<xref rid="B202-jox-14-00085" ref-type="bibr">202</xref>,<xref rid="B203-jox-14-00085" ref-type="bibr">203</xref>,<xref rid="B204-jox-14-00085" ref-type="bibr">204</xref>,<xref rid="B205-jox-14-00085" ref-type="bibr">205</xref>,<xref rid="B206-jox-14-00085" ref-type="bibr">206</xref>,<xref rid="B207-jox-14-00085" ref-type="bibr">207</xref>,<xref rid="B208-jox-14-00085" ref-type="bibr">208</xref>,<xref rid="B209-jox-14-00085" ref-type="bibr">209</xref>,<xref rid="B210-jox-14-00085" ref-type="bibr">210</xref>,<xref rid="B211-jox-14-00085" ref-type="bibr">211</xref>,<xref rid="B212-jox-14-00085" ref-type="bibr">212</xref>,<xref rid="B213-jox-14-00085" ref-type="bibr">213</xref>,<xref rid="B214-jox-14-00085" ref-type="bibr">214</xref>,<xref rid="B215-jox-14-00085" ref-type="bibr">215</xref>,<xref rid="B216-jox-14-00085" ref-type="bibr">216</xref>,<xref rid="B217-jox-14-00085" ref-type="bibr">217</xref>,<xref rid="B218-jox-14-00085" ref-type="bibr">218</xref>,<xref rid="B219-jox-14-00085" ref-type="bibr">219</xref>,<xref rid="B220-jox-14-00085" ref-type="bibr">220</xref>,<xref rid="B221-jox-14-00085" ref-type="bibr">221</xref>,<xref rid="B222-jox-14-00085" ref-type="bibr">222</xref>,<xref rid="B223-jox-14-00085" ref-type="bibr">223</xref>,<xref rid="B224-jox-14-00085" ref-type="bibr">224</xref>,<xref rid="B225-jox-14-00085" ref-type="bibr">225</xref>,<xref rid="B226-jox-14-00085" ref-type="bibr">226</xref>,<xref rid="B227-jox-14-00085" ref-type="bibr">227</xref>,<xref rid="B228-jox-14-00085" ref-type="bibr">228</xref>]. For 20 cases from an original cohort study, additional primary data were provided by the authors [<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>].</p><sec id="sec3dot2dot1-jox-14-00085"><title>3.2.1. Dose&#8211;Concentration Correlation</title><p>The ingested QTP dose and the measured c<sub>max</sub> demonstrated a weak but significant correlation using Pearson&#8217;s correlation coefficient (r = 0.256; N = 63; <italic toggle="yes">p</italic> = 0.043). Since large discrepancies were observed in several cases, it is questionable whether the measured concentrations in these cases really corresponded to the c<sub>max</sub>. In addition, the information on QTP dose and the time of ingestion may have been inaccurate. If only the cases with a reliable medical history were analysed, the correlation would probably be stronger. Uncertainties related to dose and the time of ingestion have previously been used to improve the stability of a predictive model [<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>]. However, a relatively weak correlation between dose and exposure appears to be inherent to QTP, as evidenced by population pharmacokinetic analyses, demonstrating large interindividual variability even at therapeutic doses [<xref rid="B42-jox-14-00085" ref-type="bibr">42</xref>]. Therefore, the measurement of QTP concentration is advised to predict the toxicodynamic profile.</p><p>Of the 58 cases with an estimated time between ingestion and concentration measurements, 32 had multiple concentration measurements performed. One hundred and sixty-three concentration points are included in the dose-normalised concentration&#8211;time analysis (<xref rid="jox-14-00085-f001" ref-type="fig">Figure 1</xref>).</p><p>Based on the elimination rate constant (k<sub>e</sub>) of 0.042/h, the typical t<sub>1/2</sub> was 16.5 h. In the cases where no decontamination was performed, a stagnant concentration trend line was observed for 30 h post-ingestion, suggesting that the absence of decontamination causes a delayed t<sub>max</sub> and a delayed (or extended) concentration peak. <xref rid="jox-14-00085-f002" ref-type="fig">Figure 2</xref> shows the ingestions of IR and XR formulations separately; cases with unknown formulations are not included.</p><p>The estimated t<sub>1/2</sub> was similar for both formulations. However, a biphasic disposition cannot be excluded for the IR form, with an initial t<sub>1/2</sub> of 5.8 h (within 20 h post-ingestion, probably with a significant influence of the distribution) and a longer terminal t<sub>1/2</sub> of 27.7 h (&gt;20 h post-ingestion). Thus, the estimated initial t<sub>1/2</sub> corresponded to the therapeutic t<sub>1/2</sub>.</p><p>A median t<sub>1/2</sub> of 6.6 h was previously reported in a clinical evaluation of the effect of activated charcoal in 54 intoxication events [<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>]. The authors developed a one-compartment model with first-order absorption and first-order elimination that described the observed data. However, other studies and case reports demonstrated conflicting findings, and biphasic elimination was suggested in several cases [<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>,<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>]. This could indicate the presence of a third compartment, bezoar formation or hepatic redistribution [<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B85-jox-14-00085" ref-type="bibr">85</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>]. Saturated hepatic metabolism is not very likely. The reported c<sub>max</sub> values are several times lower than the previously estimated in vitro K<sub>m</sub> values for the formation of QTP metabolites [<xref rid="B57-jox-14-00085" ref-type="bibr">57</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>]. QTP was detected in plasma for a maximum of 7 days post-ingestion [<xref rid="B47-jox-14-00085" ref-type="bibr">47</xref>]. In the terminal phase, the rate of decline in QTP concentrations may be significantly reduced due to redistribution from a third compartment or the release of QTP from bezoars in the gastrointestinal tract. A slower elimination rate in the terminal phase could explain the longer duration of clinical symptoms in several described cases [<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>].</p><p>A second concentration peak was noted in 12 cases, five of which were intoxications with the XR form; in an additional four cases, the formulation was not explicitly stated. Activated charcoal was used in three cases, and gastric lavage was performed in five cases. Pharmacobezoar formation was recognised in three cases [<xref rid="B164-jox-14-00085" ref-type="bibr">164</xref>,<xref rid="B204-jox-14-00085" ref-type="bibr">204</xref>]. One case was a probable drug interaction with antiretroviral therapy [<xref rid="B56-jox-14-00085" ref-type="bibr">56</xref>]. The second concentration peak occurred between 20 and 56 h post-ingestion.</p><p>In the case of a 39-year-old female patient who had ingested 30 g of QTP (formulation unknown), norQTP concentrations were measured. The c<sub>max</sub> of 10.2 &#181;mol/L was reached 62 h post-admission, and the concentrations were still elevated after 80 h. The possibility of pharmacobezoar formation was not discussed [<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>,<xref rid="B228-jox-14-00085" ref-type="bibr">228</xref>]. Vignali et al. found norQTP in significant concentrations in 13 postmortem cases. The femoral blood concentrations of norQTP exceeded those of QTP in four cases. The correlation between QTP and norQTP may be useful in determining the time and route of ingestion [<xref rid="B60-jox-14-00085" ref-type="bibr">60</xref>].</p></sec><sec id="sec3dot2dot2-jox-14-00085"><title>3.2.2. Relationship Between Dose or Concentration and Clinical Presentation</title><p><xref rid="jox-14-00085-t002" ref-type="table">Table 2</xref> shows the characteristics of the 134 patients with QTP intoxication. The median ingested QTP dose for 118 cases was 10 g (IQR 4.25&#8211;17.50 g, range 0.25&#8211;48 g), and the median c<sub>max</sub> measured in 65 cases was 4.04 mg/L (IQR 1.83&#8211;7.45 mg/L, range 0.03&#8211;38.35 mg/L).</p><p>All fatalities occurred either with QTP doses &#8805; 9 g or c<sub>max</sub> &gt; 2 mg/L (<xref rid="jox-14-00085-f003" ref-type="fig">Figure 3</xref>). The median ingested dose and median c<sub>max</sub> in fatal cases were 15 g and 13.39 mg/L, respectively. CNS depression (GCS &lt; 15) occurred in 95.5% of patients. The case distributions by dose and c<sub>max</sub> for other toxicodynamic parameters are presented in <xref rid="app1-jox-14-00085" ref-type="app">Supplementary Figures S1 and S2</xref>. To assess the relationship between dose or c<sub>max</sub> and the severity of intoxication, patients with mild to moderate symptoms (GCS &#8805; 9) were compared to patients with severe symptoms, including fatal outcomes (GCS &#8804; 8). <xref rid="jox-14-00085-t003" ref-type="table">Table 3</xref> shows the results of the logistic regression models for the severity of intoxication.</p><p>Dose and c<sub>max</sub> were good predictors of severe intoxication. Doses &gt; 3 g and c<sub>max</sub> &gt; 5 mg/L were associated with a higher risk for the lowest GCS score &#8804; 8. The previously reported dose thresholds for increasing severity of symptoms were comparable and ranged from 2.5 to 5.4 g [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B97-jox-14-00085" ref-type="bibr">97</xref>,<xref rid="B114-jox-14-00085" ref-type="bibr">114</xref>,<xref rid="B229-jox-14-00085" ref-type="bibr">229</xref>]. However, individual cases of only mild toxicity at a 20 g dose and survival after a dose of 36 g have been reported [<xref rid="B52-jox-14-00085" ref-type="bibr">52</xref>,<xref rid="B220-jox-14-00085" ref-type="bibr">220</xref>]. For the XR formulation, a dose &gt; 1.5 g and two or more coingested agents were associated with greater severity of poisoning in a retrospective study of 372 cases [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>]. Another retrospective analysis of QTP intoxications without sedative coingestants revealed a poor correlation between the ingested dose and the lowest GCS for both formulations. While the signs of peak toxicity were similar for the IR and XR forms, the time to peak toxicity was significantly longer for the XR form: 7 h vs. 3.8 h for the lowest GCS score and 9 h vs. 2.5 h for the maximum heart rate. The median time to recovery from sedation was longer for the XR form (20 h vs. 12 h after IR) [<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>].</p><p>For most toxicodynamic parameters, the ingested QTP dose and c<sub>max</sub> were higher in the &#8220;event&#8221; groups compared to the &#8220;no event&#8221; groups (<xref rid="jox-14-00085-f004" ref-type="fig">Figure 4</xref> and <xref rid="jox-14-00085-f005" ref-type="fig">Figure 5</xref>; <xref rid="app1-jox-14-00085" ref-type="app">Supplementary Table S1</xref>). Patients without heart block ingested a higher median dose than patients with heart block, and patients without rhabdomyolysis, agitation and acidosis had higher median c<sub>max</sub> values compared to the &#8220;event&#8221; groups. However, none of these differences were found to be significant in the logistic regression analyses (<xref rid="app1-jox-14-00085" ref-type="app">Supplementary Table S2</xref>).</p><p>Hyperglycaemia and seizures occurred at the highest ingested doses and c<sub>max</sub> values (median dose 16.5 g and 15 g; median c<sub>max</sub> 9.54 mg/L and 7.30 mg/L, respectively). Median doses were &gt;12 g also for intubation, tachycardia, use of vasopressors, QRS prolongation, rhabdomyolysis, agitation and delirium, while median c<sub>max</sub> values were &gt;5 mg/L for QT<sub>c</sub> prolongation, hypotension and hypokalaemia.</p><p>Using binary logistic regression with dose as a continuous variable, the differences were significant for ICU admission (OR 1.142; <italic toggle="yes">p</italic> = 0.005), intubation (OR 1.082; <italic toggle="yes">p</italic> = 0.001), tachycardia (OR 1.079; <italic toggle="yes">p</italic> = 0.040), use of vasopressors (OR 1.042; <italic toggle="yes">p</italic> = 0.043), QT<sub>c</sub> prolongation (OR 1.043; <italic toggle="yes">p</italic> = 0.041) and seizures (OR 1.051; <italic toggle="yes">p</italic> = 0.016). With dose categorisation, the risk of hypotension was higher for doses &gt;8 g compared to doses &#8804; 3 g (OR 3.070; <italic toggle="yes">p</italic> = 0.028) (<xref rid="app1-jox-14-00085" ref-type="app">Supplementary Table S2</xref>).</p><p>C<sub>max</sub> as a continuous variable was associated with ICU admission (OR 4.263; <italic toggle="yes">p</italic> = 0.023), intubation (OR 1.100; <italic toggle="yes">p</italic> = 0.001) and seizures (OR 1.110; <italic toggle="yes">p</italic> = 0.009). In addition, c<sub>max</sub> values &gt; 7 mg/L presented greater odds for the use of vasopressors (OR 14.545; <italic toggle="yes">p</italic> = 0.013), values &gt; 4 mg/L were associated with QT<sub>c</sub> prolongation (OR 4.889; <italic toggle="yes">p</italic> = 0.009) and values &gt;5 mg/L presented greater odds for hypotension, compared to c<sub>max</sub> &#8804; 2 mg/L (OR 7.500; <italic toggle="yes">p</italic> = 0.008).</p><p>The odds for ICU admission increased by 14% for every 1 g of QTP ingested and were 6-fold greater for doses between 3 and 8 g and &gt;9-fold greater for doses &gt; 8 g than for doses &#8804; 3 g. QTP concentration was a strong predictor of ICU treatment. All patients with a c<sub>max</sub> &gt; 2 mg/L were admitted to the ICU. In a published case series of 18 patients with QTP poisoning, a dose &lt; 3 g generally did not require ICU admission or hospitalisation for &gt;24 h [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>].</p><p>The risk of intubation was related to both increasing dose and concentration; the odds were 9.5-fold higher for doses &gt; 4 g QTP (compared to &#8804; 2 g), 3.5-fold higher for c<sub>max</sub> 3-8 mg/L, and 22-fold higher for c<sub>max</sub> &gt; 8 mg/L (compared to c<sub>max</sub> &lt; 3 mg/L). In a cohort study of 286 QTP intoxication events, the risk of intubation was dose-dependent, increasing from 10% at a dose of 2 g, 22% at 5 g, 37% at 10 g, and 55% at 20 g [<xref rid="B48-jox-14-00085" ref-type="bibr">48</xref>,<xref rid="B106-jox-14-00085" ref-type="bibr">106</xref>]. The median dose in intubated patients was 5 g (IQR 2.52&#8211;11.85 g) [<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>]. Taylor and Graudins found a higher ingested dose (median 5.8 g) in patients requiring intubation (median 2 g in non-intubated patients). The duration of intubation was significantly longer after ingestion of the XR form compared to the IR form (47 h and 17 h, respectively). However, the ingested doses of the XR form in the study were significantly higher (5.7 g vs. 1.75 g for the IR form) [<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>].</p><p>Apart from CNS depression, tachycardia was the most common sign of QTP intoxication and occurred in &gt;80% of cases. The odds were 12-fold greater for doses 1&#8211;10 g and 44-fold greater for doses &gt; 10 g than for doses &lt; 1 g. We also observed a trend of increased risk of tachycardia for c<sub>max</sub> &gt; 4 mg/L (OR 8.348; <italic toggle="yes">p</italic> = 0.054). There was only one case with c<sub>max</sub> &gt; 5 mg/L and without tachycardia (compared to 20 cases with tachycardia at c<sub>max</sub> &gt; 5 mg/L&#8212;<xref rid="app1-jox-14-00085" ref-type="app">Supplementary Figure S2</xref>).</p><p>The risk for hypotension was significantly associated with doses &gt; 8 g (compared to doses &#8804; 3 g) and with c<sub>max</sub> &gt; 5 mg/L (compared to c<sub>max</sub> &#8804; 2 mg/L). Similarly, doses &gt; 7 g demonstrated 4-fold greater odds for the use of vasopressors than doses &#8804; 7 g. In a retrospective analysis of 286 QTP intoxication events, a modest correlation was found between the ingested dose and the lowest systolic blood pressure [<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>].</p><p>The lowest dose associated with QT<sub>c</sub> prolongation was 1.2 g. Increasing dose was significantly correlated with QT<sub>c</sub> prolongation, confirming previous findings on QT<sub>c</sub> dose-dependence [<xref rid="B76-jox-14-00085" ref-type="bibr">76</xref>,<xref rid="B77-jox-14-00085" ref-type="bibr">77</xref>,<xref rid="B78-jox-14-00085" ref-type="bibr">78</xref>,<xref rid="B79-jox-14-00085" ref-type="bibr">79</xref>]. The odds for QT<sub>c</sub> prolongation were 5-fold greater for c<sub>max</sub> &gt; 4 mg/L. Berling and Isbister analysed the relationship between QTP dose and the risk of uncorrected QT prolongation in 202 patients and found no correlation [<xref rid="B230-jox-14-00085" ref-type="bibr">230</xref>]. Most QT prolongations occurred in patients with tachycardia (rates &gt; 105 bpm) [<xref rid="B230-jox-14-00085" ref-type="bibr">230</xref>]. In our dataset, there was no association between QT<sub>c</sub> prolongation and tachycardia (Pearson &#967;<sup>2</sup>(1, N = 103) = 1.88, <italic toggle="yes">p</italic> = 0.170). Uncorrected QT prolongation was not analysed. Several other risk factors for QT<sub>c</sub> interval prolongation are known, e.g., electrolyte imbalances, female sex, older age, pre-existing cardiac disease and drug&#8211;drug interactions [<xref rid="B129-jox-14-00085" ref-type="bibr">129</xref>,<xref rid="B132-jox-14-00085" ref-type="bibr">132</xref>], which were not assessed in this analysis.</p><p>The following arrhythmia patterns were described: ventricular tachycardia, ventricular extrasystoles, ventricular fibrillation, self-limiting ventricular bursts, (paroxysmal) supraventricular tachycardia, ectopic atrial rhythm, palpitations, atrioventricular nodal re-entry tachycardia and wide complex rhythm. Arrhythmia was rarely reported, and the number of cases included in analysis was low (seven cases with prolonged QT<sub>c</sub> interval, four cases without prolonged QT<sub>c</sub> interval, and three cases with no QT or QT<sub>c</sub> reported). The association between arrhythmia and QT<sub>c</sub> prolongation failed to reach statistical significance using Fisher&#8217;s exact test (<italic toggle="yes">p</italic> = 0.098). In published studies, acute intoxication with QTP as a single agent did not increase the risk of torsade de pointes [<xref rid="B9-jox-14-00085" ref-type="bibr">9</xref>,<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>].</p><p>There was a small but statistically significant increase of 5% in the odds of seizures for every 1 g of QTP ingested (OR 1.051, <italic toggle="yes">p</italic> = 0.016) and an increase of 10% in the odds for every 1 mg/L increase in c<sub>max</sub> value (OR 1.110, <italic toggle="yes">p</italic> = 0.009). The odds were 5-fold greater with doses &gt; 20 g (compared to doses &#8804; 10 g) and 7.5-fold greater with c<sub>max</sub> &gt; 4 mg/L. In a cohort study of 286 QTP intoxication events, all five patients who experienced seizures had ingested high doses (6&#8211;24 g) of QTP and concurrent drugs, including high doses of citalopram in two cases [<xref rid="B111-jox-14-00085" ref-type="bibr">111</xref>]. In our dataset, seizures occurred at higher dose and concentration ranges than other signs and symptoms, with the exception of hyperglycaemia (median 15 g and 7.3 mg/L, respectively). Half of these patients (17/34) had coingested clinically relevant agents.</p><p>There was no association between QTP dose or c<sub>max</sub> and the risk of QRS prolongation, arrhythmia, heart block, agitation, hypokalaemia or acidosis. There was a trend towards an increased risk of heart block at a c<sub>max</sub> &gt; 3 mg/L (OR 4.033; <italic toggle="yes">p</italic> = 0.053) and for acidosis at doses &gt; 7 g (OR 3.667; <italic toggle="yes">p</italic> = 0.057). In line with these findings, the occurrence of arrhythmias, AV block, QT<sub>c</sub> prolongation, hypokalaemia and acidosis in QTP intoxications is not as consistently described as in intoxications with several other antipsychotics [<xref rid="B136-jox-14-00085" ref-type="bibr">136</xref>,<xref rid="B231-jox-14-00085" ref-type="bibr">231</xref>,<xref rid="B232-jox-14-00085" ref-type="bibr">232</xref>]. A recent study by Tang et al. showed no significant increase in QRS prolongation (&gt;120 ms) in QTP poisoning in a large cohort of 11,945 patients with pharmaceutical overdoses [<xref rid="B233-jox-14-00085" ref-type="bibr">233</xref>].</p><p>Logistic regression analyses were not performed for rhabdomyolysis, delirium and hyperglycaemia as the number of cases in the &#8220;event&#8221; group with reported ingested dose or c<sub>max</sub> was low.</p><p>Fourteen cases with confirmed pharmacobezoar formation were included. All involved ingestion of the XR formulation with doses ranging from 3 g to 48 g. None of the cases were fatal. In a series of nine cases of bezoar formation after an overdose of XR QTP, eight patients had coingested other drugs. A gradual or rapid deterioration after several hours was typical in these cases. However, after endoscopic removal of the pharmacobezoars, none of the patients experienced significant toxicity, and all recovered within 3 days [<xref rid="B104-jox-14-00085" ref-type="bibr">104</xref>].</p><p>IR and XR forms can differ in their toxicodynamic profile. The IR form may be more likely to cause severe signs, e.g., coma and respiratory depression, in the first hours post-ingestion due to higher c<sub>max</sub> [<xref rid="B29-jox-14-00085" ref-type="bibr">29</xref>]. On the other hand, symptoms may be prolonged with the XR form, especially if no decontamination has been performed. Fifty-eight of the included patients ingested other clinically relevant agents, most commonly ethanol, benzodiazepines, antidepressants and other antipsychotics, similar to previous reports [<xref rid="B26-jox-14-00085" ref-type="bibr">26</xref>]. Information on the ingested formulation was frequently missing from the reports. It was not feasible to include the QTP formulation, coingested agents or decontamination procedures as covariates in the statistical models with the collected dataset.</p><p>In summary, higher QTP dose and concentration were significantly associated with the lowest GCS score, ICU admission, intubation, hypotension, use of vasopressors, QT<sub>c</sub> prolongation and seizures. Dose, but not concentration, was also associated with tachycardia. The thresholds for increased risk of these events were variable, between 3 g and 20 g for QTP dose and between 2 mg/L and 7 mg/L for QTP concentration. Therefore, doses &gt; 3 g and concentrations &gt; 2 mg/L presented a higher risk of a severe clinical presentation. The probabilities for the parameters, significantly associated with QTP dose and concentration, below and above the 3 g dose and 2 mg/L concentration thresholds are presented in <xref rid="app1-jox-14-00085" ref-type="app">Supplementary Figures S3 and S4</xref>.</p></sec></sec></sec><sec id="sec4-jox-14-00085"><title>4. Limitations</title><p>The reliability of data in the context of intoxication may be questionable. In the existing studies, obtaining accurate information on the dose and time of ingestion presented a challenge, and it was often not documented [<xref rid="B1-jox-14-00085" ref-type="bibr">1</xref>]. In addition, reviewing cases from the literature presents a limitation, as publications may contain different amounts and types of data, and gaining additional information is not possible. Therefore, not all parameters of interest can be captured for every included case. Due to the heterogeneity of data from published reports and studies on acute QTP intoxication, a systematic review was not conducted. However, the literature search, data collection and analysis were clearly structured and described.</p><p>With the collected dataset, it was not possible to perform statistical analyses with multiple covariates, as data for different parameters were frequently missing from the references. Imputation, maximum likelihood or a similar method to include missing values was not attempted. Coingestion of other agents was one of the factors that undoubtedly had an impact on the clinical presentation in several cases but was not evaluated.</p><p>The frequencies for clinical events, signs and symptoms in the analysis do not represent true incidences, as they are based on published case reports and series and not on population data. The inclusion of published cases has inevitably led to a bias towards more severe cases, as asymptomatic and mild intoxications are not usually published.</p><p>The lack of a significant correlation between QTP dose or c<sub>max</sub> and several toxicodynamic parameters does not mean that these signs and symptoms do not occur in acute QTP intoxication. Rather, it indicates that they may occur regardless of the dose taken or the concentration measured when the QTP dose exceeds the upper therapeutic limit of 800 mg. None of the dynamic parameters were analysed as continuous variables. Therefore, the exact pattern of this relationship cannot be assessed using the data collected from the literature.</p></sec><sec sec-type="conclusions" id="sec5-jox-14-00085"><title>5. Conclusions</title><p>In this structured literature review and analysis of acute QTP intoxication cases, the typical t<sub>1/2</sub> (16.5 h) was longer than for therapeutic doses. Decontamination procedures may have significantly reduced t<sub>max</sub>, c<sub>max</sub> and estimated t<sub>1/2</sub>. The ingested QTP dose and c<sub>max</sub> were significantly correlated. CNS depression (GCS &lt; 15) and tachycardia were the most common signs of QTP intoxication. Dose as a continuous variable was generally a better predictor of clinical events than c<sub>max</sub>. However, with dose and c<sub>max</sub> categorisation, both were significantly correlated with the same clinical events. Higher doses and c<sub>max</sub> values increased the risk of ICU admission, intubation, hypotension, use of vasopressors, QT<sub>c</sub> prolongation and seizures, but not QRS prolongation, arrhythmia, heart block, agitation, hypokalaemia or acidosis. Tachycardia was associated with increasing doses and was short of a significant correlation with c<sub>max</sub>. The dose thresholds for an increased risk of &#8220;event&#8221; for individual toxicodynamic parameters were typically between 3 g and 7 g (20 g for seizures and QT<sub>c</sub> prolongation), and the c<sub>max</sub> thresholds were between 2 mg/L and 4 mg/L (7 mg/L for the use of vasopressors). Therefore, doses &gt; 3 g and c<sub>max</sub> &gt; 2 mg/L may be considered alert levels for high risk of severe complications in acute QTP intoxication.</p><p>Patients ingesting &gt;3 g of QTP should be observed at the Emergency Department and may be transferred to a psychiatric unit no sooner than after 6 h if no severe signs and symptoms are present. The type of formulation (IR or XR) should be specified together with the dose. If ingestion of XR QTP is suspected, patients may require longer, e.g., 12 h observation. Prompt decontamination (e.g., use of activated charcoal within 6 h post-ingestion) is likely to improve the clinical course of intoxication. If a serum QTP concentration measurement is available on site, sampling upon admission, but not earlier than 2 h post-ingestion, is recommended to confirm or exclude the intoxication with QTP. A concentration &gt; 2 mg/L indicates a severe, potentially lethal intoxication. However, lower concentrations may still anticipate a severe clinical course, depending on the time from ingestion to sampling, so caution is required when interpreting concentration results.</p></sec><sec id="sec6-jox-14-00085"><title>6. Future Directions</title><p>Future studies may investigate closely the duration of common signs and symptoms, particularly when evaluating treatment strategies. The reports on QTP intoxication should state the formulation (IR or XR) that may influence the clinical course and is relevant for clinical decision-making. Determining the concentration&#8211;time relationship for two analytes, QTP and its active metabolite norQTP, could be informative. The measurement of both analytes in clinical practice might improve the estimation of the time from ingestion to sampling.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-jox-14-00085"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/jox14040085/s1">https://www.mdpi.com/article/10.3390/jox14040085/s1</uri>, Figure S1: Toxicodynamic parameters&#8212;case distribution by dose; Figure S2: Toxicodynamic parameters&#8212;case distribution by peak concentration; Figure S3: Toxicodynamic parameters&#8212;probabilities with quetiapine dose below and above 3 g; Figure S4: Toxicodynamic parameters&#8212;probabilities with quetiapine concentration below and above 2 mg/l; Table S1: Dose and peak concentration data for toxicodynamic parameters; Table S2: Toxicodynamic parameters&#8212;logistic regression results.</p><supplementary-material id="jox-14-00085-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jox-14-00085-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualisation, M.D.V., I.G. and M.B.; methodology, M.D.V. and I.G.; literature search, M.D.V. and F.E.; data analysis, M.D.V., F.E. and I.G.; resources, M.B.; data curation, M.D.V.; writing&#8212;original draft preparation, M.D.V.; writing&#8212;review and editing, M.D.V., I.G., F.E. and M.B.; visualisation, M.D.V.; supervision, M.B.; project administration, M.B.; funding acquisition, M.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created in this study. Statistical analyses are provided as <xref rid="app1-jox-14-00085" ref-type="app">Supplementary Materials</xref>. A data spreadsheet with collected information on the cases included in the analysis is available upon request from the authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jox-14-00085"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciranni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>K.R.</given-names></name></person-group><article-title>Acute Quetiapine Overdose in Adults: A 5-Year Retrospective Case Series</article-title><source>Ann. Emerg. Med.</source><year>2008</year><volume>52</volume><fpage>541</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2008.03.016</pub-id><pub-id pub-id-type="pmid">18433934</pub-id></element-citation></ref><ref id="B2-jox-14-00085"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balit</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Isbister</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Whyte</surname><given-names>I.M.</given-names></name></person-group><article-title>Quetiapine Poisoning: A Case Series</article-title><source>Ann. Emerg. Med.</source><year>2003</year><volume>42</volume><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/S0196-0644(03)00600-0</pub-id><pub-id pub-id-type="pmid">14634598</pub-id></element-citation></ref><ref id="B3-jox-14-00085"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vento</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Kotzalidis</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Cacciotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papanti</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Orsolini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rapinesi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Savoja</surname><given-names>V.</given-names></name><name name-style="western"><surname>Calabr&#242;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Del Casale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piacentino</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review</article-title><source>Subst. Use Misuse</source><year>2020</year><volume>55</volume><fpage>304</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1080/10826084.2019.1668013</pub-id><pub-id pub-id-type="pmid">31573374</pub-id></element-citation></ref><ref id="B4-jox-14-00085"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philip</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Mello</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Tyrka</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Price</surname><given-names>L.H.</given-names></name></person-group><article-title>Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use</article-title><source>Ann. Clin. Psychiatry</source><year>2008</year><volume>20</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1080/10401230701866870</pub-id><pub-id pub-id-type="pmid">18297582</pub-id></element-citation></ref><ref id="B5-jox-14-00085"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>D.L.</given-names></name></person-group><article-title>Off-label prescription of quetiapine in psychiatric disorders</article-title><source>Expert. Rev. Neurother.</source><year>2007</year><volume>7</volume><fpage>841</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1586/14737175.7.7.841</pub-id><pub-id pub-id-type="pmid">17610391</pub-id></element-citation></ref><ref id="B6-jox-14-00085"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pir&#243;g-Balcerzak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Habrat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mierzejewski</surname><given-names>P.</given-names></name></person-group><article-title>Misuse and abuse of quetiapine</article-title><source>Psychiatr. Pol.</source><year>2015</year><volume>49</volume><fpage>81</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.12740/PP/32923</pub-id><pub-id pub-id-type="pmid">25844412</pub-id></element-citation></ref><ref id="B7-jox-14-00085"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huthwaite</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cleghorn</surname><given-names>M.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>J.</given-names></name></person-group><article-title>&#8220;Out of the frying pan&#8221;: The challenges of prescribing for insomnia in psychiatric patients</article-title><source>Australas. Psychiatry</source><year>2014</year><volume>22</volume><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1177/1039856214530015</pub-id><pub-id pub-id-type="pmid">24696412</pub-id></element-citation></ref><ref id="B8-jox-14-00085"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brett</surname><given-names>J.</given-names></name></person-group><article-title>Concerns about quetiapine</article-title><source>Aust. Prescr.</source><year>2015</year><volume>38</volume><fpage>95</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.18773/austprescr.2015.032</pub-id><pub-id pub-id-type="pmid">26648630</pub-id><pub-id pub-id-type="pmcid">PMC4653966</pub-id></element-citation></ref><ref id="B9-jox-14-00085"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montebello</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Brett</surname><given-names>J.</given-names></name></person-group><article-title>Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics</article-title><source>Curr. Top. Behav. Neurosci.</source><year>2015</year><volume>34</volume><fpage>125</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1007/7854_2015_424</pub-id><pub-id pub-id-type="pmid">26695164</pub-id></element-citation></ref><ref id="B10-jox-14-00085"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>L.</given-names></name><name name-style="western"><surname>Graudins</surname><given-names>A.</given-names></name></person-group><article-title>Extended-release quetiapine overdose is associated with delayed onset of toxicity compared to immediate-release quetiapine overdose</article-title><source>EMA Emerg. Med. Australas.</source><year>2019</year><volume>31</volume><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1111/1742-6723.13205</pub-id><pub-id pub-id-type="pmid">30485698</pub-id></element-citation></ref><ref id="B11-jox-14-00085"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charreteur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peries</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kheloufi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eiden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nagot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Donnadieu-Rigole</surname><given-names>H.</given-names></name><name name-style="western"><surname>Micallef</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peyri&#232;re</surname><given-names>H.</given-names></name></person-group><article-title>Abuse and misuse of second-generation antipsychotics: An analysis using VigiBase, the World Health Organisation pharmacovigilance database</article-title><source>Br. J. Clin. Pharmacol.</source><year>2022</year><volume>88</volume><fpage>4646</fpage><lpage>4653</lpage><pub-id pub-id-type="doi">10.1111/bcp.15420</pub-id><pub-id pub-id-type="pmid">35633029</pub-id></element-citation></ref><ref id="B12-jox-14-00085"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brigadeiro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu&#237;s</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>J.</given-names></name></person-group><article-title>Acute quetiapine overdose is associated with risk of ectopic atrial rhythm</article-title><source>Actas Espa&#241;olas Psiquiatr.</source><year>2023</year><volume>51</volume><fpage>216</fpage><lpage>219</lpage><pub-id pub-id-type="pmcid">PMC10803843</pub-id><pub-id pub-id-type="pmid">38117261</pub-id></element-citation></ref><ref id="B13-jox-14-00085"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephenson</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Karanges</surname><given-names>E.</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>I.S.</given-names></name></person-group><article-title>Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2013</year><volume>47</volume><fpage>74</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1177/0004867412466595</pub-id><pub-id pub-id-type="pmid">23144164</pub-id></element-citation></ref><ref id="B14-jox-14-00085"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modesto-Lowe</surname><given-names>V.</given-names></name><name name-style="western"><surname>Harabasz</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>S.A.</given-names></name></person-group><article-title>Quetiapine for primary insomnia: Consider the risks</article-title><source>Cleve Clin. J. Med.</source><year>2021</year><volume>88</volume><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.3949/ccjm.88a.20031</pub-id><pub-id pub-id-type="pmid">33941603</pub-id></element-citation></ref><ref id="B15-jox-14-00085"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenqvist</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Osler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wium-Andersen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Wium-Andersen</surname><given-names>I.K.</given-names></name></person-group><article-title>Sedative drug-use in Denmark, 2000 to 2019: A nationwide drug utilization study</article-title><source>Soc. Psychiatry Psychiatr. Epidemiol.</source><year>2023</year><volume>58</volume><fpage>1493</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1007/s00127-022-02409-5</pub-id><pub-id pub-id-type="pmid">36562827</pub-id></element-citation></ref><ref id="B16-jox-14-00085"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radha Krishnan</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Raubenheimer</surname><given-names>J.E.</given-names></name></person-group><article-title>On- and off-label utilisation of antipsychotics in Australia (2000&#8211;2021): Retrospective analysis of two medication datasets</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2024</year><volume>58</volume><fpage>320</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1177/00048674231210209</pub-id><pub-id pub-id-type="pmid">37941354</pub-id><pub-id pub-id-type="pmcid">PMC10960313</pub-id></element-citation></ref><ref id="B17-jox-14-00085"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Theodoros</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Isoardi</surname><given-names>K.Z.</given-names></name></person-group><article-title>Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: A retrospective series</article-title><source>Australas. Psychiatry</source><year>2023</year><volume>31</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1177/10398562231153009</pub-id><pub-id pub-id-type="pmid">36772817</pub-id><pub-id pub-id-type="pmcid">PMC10088345</pub-id></element-citation></ref><ref id="B18-jox-14-00085"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattson</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Albright</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Council</surname><given-names>C.L.</given-names></name></person-group><article-title>Emergency department visits involving misuse and abuse of the antipsychotic quetiapine: Results from the drug abuse warning network (DAWN)</article-title><source>Subst. Abus. Res. Treat.</source><year>2015</year><volume>9</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.4137/SART.S22233</pub-id><pub-id pub-id-type="pmcid">PMC4444129</pub-id><pub-id pub-id-type="pmid">26056465</pub-id></element-citation></ref><ref id="B19-jox-14-00085"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiappini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schifano</surname><given-names>F.</given-names></name></person-group><article-title>Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions&#8217; Database</article-title><source>J. Clin. Pharmacol.</source><year>2018</year><volume>38</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000814</pub-id><pub-id pub-id-type="pmid">29210868</pub-id></element-citation></ref><ref id="B20-jox-14-00085"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutherland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jayathilake</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dietze</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gisev</surname><given-names>N.</given-names></name></person-group><article-title>Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011&#8211;2018</article-title><source>Drug Alcohol Depend</source><year>2021</year><volume>221</volume><fpage>108636</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108636</pub-id><pub-id pub-id-type="pmid">33631549</pub-id></element-citation></ref><ref id="B21-jox-14-00085"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breivik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#248;kken</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Sl&#248;rdal</surname><given-names>L.</given-names></name></person-group><article-title>Post mortem tissue distribution of quetiapine in forensic autopsies</article-title><source>Forensic Sci. Int.</source><year>2020</year><volume>315</volume><fpage>110413</fpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2020.110413</pub-id><pub-id pub-id-type="pmid">32745884</pub-id></element-citation></ref><ref id="B22-jox-14-00085"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indave</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Minozzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pani</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Amato</surname><given-names>L.</given-names></name></person-group><article-title>Antipsychotic medications for cocaine dependence</article-title><source>Cochrane Database Syst. Rev.</source><year>2016</year><volume>3</volume><fpage>CD006306</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD006306.pub3</pub-id><pub-id pub-id-type="pmid">26992929</pub-id><pub-id pub-id-type="pmcid">PMC8750745</pub-id></element-citation></ref><ref id="B23-jox-14-00085"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>R.</given-names></name></person-group><article-title>Overdose and Treatment of Quetiapine Ingestions</article-title><source>J. Emerg. Nurs.</source><year>2007</year><volume>33</volume><fpage>582</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.jen.2007.09.002</pub-id><pub-id pub-id-type="pmid">18035179</pub-id></element-citation></ref><ref id="B24-jox-14-00085"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobravc Verbi&#269;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grabnar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brvar</surname><given-names>M.</given-names></name></person-group><article-title>Association between Prescribing and Intoxication Rates for Selected Psychotropic Drugs: A Longitudinal Observational Study</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>143</elocation-id><pub-id pub-id-type="doi">10.3390/ph17010143</pub-id><pub-id pub-id-type="pmid">38276016</pub-id><pub-id pub-id-type="pmcid">PMC10818633</pub-id></element-citation></ref><ref id="B25-jox-14-00085"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Methling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krumbiegel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parr</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Tsokos</surname><given-names>M.</given-names></name></person-group><article-title>Toxicological findings in suicides&#8212;Frequency of antidepressant and antipsychotic substances</article-title><source>Forensic Sci. Med. Pathol.</source><year>2019</year><volume>15</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s12024-018-0041-4</pub-id><pub-id pub-id-type="pmid">30397872</pub-id></element-citation></ref><ref id="B26-jox-14-00085"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peridy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Gohier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Boels</surname><given-names>D.</given-names></name></person-group><article-title>Quetiapine poisoning and factors influencing severity</article-title><source>J. Clin. sychopharmacol</source><year>2019</year><volume>39</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000001053</pub-id><pub-id pub-id-type="pmid">31205192</pub-id></element-citation></ref><ref id="B27-jox-14-00085"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eyer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pfab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Felgenhauer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Strubel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saugel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zilker</surname><given-names>T.</given-names></name></person-group><article-title>Clinical and analytical features of severe suicidal quetiapine overdoses&#8212;A retrospective cohort study</article-title><source>Clin. Toxicol.</source><year>2011</year><volume>49</volume><fpage>846</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.3109/15563650.2011.624100</pub-id><pub-id pub-id-type="pmid">22077248</pub-id></element-citation></ref><ref id="B28-jox-14-00085"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunfeld</surname><given-names>N.G.M.</given-names></name><name name-style="western"><surname>Westerman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Boswijk</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>De Haas</surname><given-names>J.A.M.</given-names></name><name name-style="western"><surname>Van Putten</surname><given-names>M.J.A.M.</given-names></name><name name-style="western"><surname>Touw</surname><given-names>D.J.</given-names></name></person-group><article-title>Quetiapine in overdosage: A clinical and pharmacokinetic analysis of 14 cases</article-title><source>Ther. Drug Monit.</source><year>2006</year><volume>28</volume><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1097/01.ftd.0000185770.44502.51</pub-id><pub-id pub-id-type="pmid">16628129</pub-id></element-citation></ref><ref id="B29-jox-14-00085"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capuano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vestini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ianniello</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rafaniello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mucci</surname><given-names>A.</given-names></name></person-group><article-title>Survival from coma induced by an intentional 36-g overdose of extended-release quetiapine</article-title><source>Drug Chem. Toxicol.</source><year>2011</year><volume>34</volume><fpage>475</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.3109/01480545.2011.564178</pub-id><pub-id pub-id-type="pmid">21770717</pub-id></element-citation></ref><ref id="B30-jox-14-00085"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chenafi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaffal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soichot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Labat</surname><given-names>L.</given-names></name><name name-style="western"><surname>Megarbane</surname><given-names>B.</given-names></name></person-group><article-title>Acute quetiapine poisoning admitted in the intensive care unit: Features, complications and usefulness of plasma concentration measurement</article-title><source>Clin. Toxicol.</source><year>2019</year><volume>57</volume><fpage>571</fpage></element-citation></ref><ref id="B31-jox-14-00085"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#233;garbane</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oberlin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Balen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Beaune</surname><given-names>S.</given-names></name><name name-style="western"><surname>B&#233;dry</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chauvin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Claudet</surname><given-names>I.</given-names></name><name name-style="western"><surname>Danel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Debaty</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Management of pharmaceutical and recreational drug poisoning</article-title><source>Ann. Intensive Care</source><year>2020</year><volume>10</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s13613-020-00762-9</pub-id><pub-id pub-id-type="pmid">33226502</pub-id><pub-id pub-id-type="pmcid">PMC7683636</pub-id></element-citation></ref><ref id="B32-jox-14-00085"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riedel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Musil</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spellmann</surname><given-names>I.</given-names></name><name name-style="western"><surname>Seem&#252;ller</surname><given-names>F.</given-names></name><name name-style="western"><surname>M&#246;ller</surname><given-names>H.-J.</given-names></name></person-group><article-title>Quetiapine XR&#8212;A new retard formulation in the treatment of schizophrenia</article-title><source>Eur. Psychiatr. Rev.</source><year>2008</year><volume>1</volume><fpage>70</fpage><lpage>75</lpage></element-citation></ref><ref id="B33-jox-14-00085"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertol</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vaiano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Argo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zerbo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trignano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Protani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Favretto</surname><given-names>D.</given-names></name></person-group><article-title>Overdose of quetiapine&#8212;A case report with QT prolongation</article-title><source>Toxics</source><year>2021</year><volume>9</volume><elocation-id>339</elocation-id><pub-id pub-id-type="doi">10.3390/toxics9120339</pub-id><pub-id pub-id-type="pmid">34941773</pub-id><pub-id pub-id-type="pmcid">PMC8703483</pub-id></element-citation></ref><ref id="B34-jox-14-00085"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devane</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Nemeroff</surname><given-names>C.B.</given-names></name></person-group><article-title>Clinical pharmacokinetics of quetiapine</article-title><source>Clin. Pharmacokinet.</source><year>2001</year><volume>40</volume><fpage>509</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.2165/00003088-200140070-00003</pub-id><pub-id pub-id-type="pmid">11510628</pub-id></element-citation></ref><ref id="B35-jox-14-00085"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isbister</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Duffull</surname><given-names>S.B.</given-names></name></person-group><article-title>Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal</article-title><source>Clin. Pharmacol. Ther.</source><year>2007</year><volume>81</volume><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100193</pub-id><pub-id pub-id-type="pmid">17410121</pub-id></element-citation></ref><ref id="B36-jox-14-00085"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Earley</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Hamer-Maansson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name></person-group><article-title>Steady-State Pharmacokinetic, Safety, and Tolerability Profiles of Quetiapine, Norquetiapine, and Other Quetiapine Metabolites in Pediatric and Adult Patients with Psychotic Disorders</article-title><source>J. Child. Adolesc. Psychopharmacol.</source><year>2008</year><volume>18</volume><fpage>81</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1089/cap.2007.0084</pub-id><pub-id pub-id-type="pmid">18294091</pub-id></element-citation></ref><ref id="B37-jox-14-00085"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauri</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Volonteri</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Colasanti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fiorentini</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Gaspari</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Bareggi</surname><given-names>S.R.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Atypical Antipsychotics</article-title><source>Clin. Pharmacokinet.</source><year>2007</year><volume>46</volume><fpage>359</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.2165/00003088-200746050-00001</pub-id><pub-id pub-id-type="pmid">17465637</pub-id></element-citation></ref><ref id="B38-jox-14-00085"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gefvert</surname><given-names>O.</given-names></name></person-group><article-title>Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection</article-title><source>J. Pharm. Biomed. Anal.</source><year>1999</year><volume>20</volume><fpage>271</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S0731-7085(99)00036-9</pub-id><pub-id pub-id-type="pmid">10704032</pub-id></element-citation></ref><ref id="B39-jox-14-00085"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bui</surname><given-names>K.</given-names></name><name name-style="western"><surname>Earley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): Clinical implications</article-title><source>Curr. Med. Res. Opin.</source><year>2013</year><volume>29</volume><fpage>813</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1185/03007995.2013.794774</pub-id><pub-id pub-id-type="pmid">23574265</pub-id></element-citation></ref><ref id="B40-jox-14-00085"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Zbuk</surname><given-names>K.</given-names></name></person-group><article-title>Quetiapine fumarate overdose: Clinical and pharmacokinetic lessons from extreme conditions</article-title><source>Clin. Pharmacol. Ther.</source><year>2000</year><volume>68</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.107507</pub-id><pub-id pub-id-type="pmid">10945320</pub-id></element-citation></ref><ref id="B41-jox-14-00085"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>K.H.</given-names></name></person-group><article-title>Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents</article-title><source>Biopharm. Drug Dispos.</source><year>2014</year><volume>35</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1002/bdd.1899</pub-id><pub-id pub-id-type="pmid">24797229</pub-id></element-citation></ref><ref id="B42-jox-14-00085"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bigos</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bies</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Marder</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>B.G.</given-names></name></person-group><article-title>Population pharmacokinetics of antipsychotics</article-title><source>Antipsychotic Trials in Schizophrenia: The CATIE Project</source><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2010</year><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1017/CBO9780511712265.016</pub-id></element-citation></ref><ref id="B43-jox-14-00085"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bies</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dolton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Day</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Polasek</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A.</given-names></name></person-group><article-title>Optimal sampling of antipsychotic medicines: A pharmacometric approach for clinical practice</article-title><source>Br. J. Clin. Pharmacol.</source><year>2014</year><volume>78</volume><fpage>800</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1111/bcp.12410</pub-id><pub-id pub-id-type="pmid">24773369</pub-id><pub-id pub-id-type="pmcid">PMC4239974</pub-id></element-citation></ref><ref id="B44-jox-14-00085"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimko</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Reele</surname><given-names>S.S.B.</given-names></name><name name-style="western"><surname>Holford</surname><given-names>N.H.G.</given-names></name><name name-style="western"><surname>Peck</surname><given-names>C.C.</given-names></name></person-group><article-title>Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model</article-title><source>Clin. Pharmacol. Ther.</source><year>2000</year><volume>68</volume><fpage>568</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.110975</pub-id><pub-id pub-id-type="pmid">11103759</pub-id></element-citation></ref><ref id="B45-jox-14-00085"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Al-Huniti</surname><given-names>N.</given-names></name></person-group><article-title>Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder</article-title><source>J. Clin. Pharmacol.</source><year>2015</year><volume>55</volume><fpage>1248</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1002/jcph.544</pub-id><pub-id pub-id-type="pmid">25975812</pub-id></element-citation></ref><ref id="B46-jox-14-00085"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukushi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Katashima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Komatsu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>A.</given-names></name></person-group><article-title>Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression</article-title><source>Clin. Ther.</source><year>2020</year><volume>42</volume><fpage>1067</fpage><lpage>1076.e2</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2020.04.006</pub-id><pub-id pub-id-type="pmid">32518042</pub-id></element-citation></ref><ref id="B47-jox-14-00085"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Kaliciak</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Carlyle</surname><given-names>S.</given-names></name></person-group><article-title>Fatal overdoses associated with quetiapine</article-title><source>J. Anal. Toxicol.</source><year>2004</year><volume>28</volume><fpage>520</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1093/jat/28.6.520</pub-id><pub-id pub-id-type="pmid">15516308</pub-id></element-citation></ref><ref id="B48-jox-14-00085"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopenwasser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mozayani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Danielson</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Harbin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Narula</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Posey</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Shrode</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>L.A.</given-names></name></person-group><article-title>Postmortem Distribution of the Novel Antipsychotic Drug Quetiapine</article-title><source>J. Anal. Toxicol.</source><year>2004</year><volume>28</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/jat/28.4.264</pub-id><pub-id pub-id-type="pmid">15189678</pub-id></element-citation></ref><ref id="B49-jox-14-00085"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrickson</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Morocco</surname><given-names>A.P.</given-names></name></person-group><article-title>Quetiapine cross-reactivity among three tricyclic antidepressant immunoassays</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2003</year><volume>41</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1081/CLT-120019122</pub-id><pub-id pub-id-type="pmid">12733845</pub-id></element-citation></ref><ref id="B50-jox-14-00085"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Datto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berggren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>H.</given-names></name></person-group><article-title>Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: A randomized, double-blind, crossover study in healthy adult subjects</article-title><source>Clin. Ther.</source><year>2009</year><volume>31</volume><fpage>492</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2009.03.002</pub-id><pub-id pub-id-type="pmid">19393840</pub-id></element-citation></ref><ref id="B51-jox-14-00085"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauri</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Paletta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Pace</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reggiori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cirnigliaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Valli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Altamura</surname><given-names>A.C.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Atypical Antipsychotics: An Update</article-title><source>Clin. Pharmacokit</source><year>2018</year><volume>57</volume><fpage>1493</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1007/s40262-018-0664-3</pub-id><pub-id pub-id-type="pmid">29915922</pub-id></element-citation></ref><ref id="B52-jox-14-00085"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dohmen</surname><given-names>C.</given-names></name></person-group><article-title>Intoxication after Extreme Oral Overdose of Quetiapine to Attempt Suicide: Pharmacological Concerns of Side Effects</article-title><source>Case Rep. Med.</source><year>2009</year><volume>2009</volume><fpage>371698</fpage><pub-id pub-id-type="doi">10.1155/2009/371698</pub-id><pub-id pub-id-type="pmid">20066171</pub-id><pub-id pub-id-type="pmcid">PMC2804057</pub-id></element-citation></ref><ref id="B53-jox-14-00085"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>I.M.</given-names></name></person-group><article-title>Case studies of postmortem quetiapine: Therapeutic or toxic concentrations?</article-title><source>J. Anal. Toxicol.</source><year>2005</year><volume>29</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1093/jat/29.5.407</pub-id><pub-id pub-id-type="pmid">16105271</pub-id></element-citation></ref><ref id="B54-jox-14-00085"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hadley</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Midtrevold</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edvardsen</surname><given-names>H.M.E.</given-names></name><name name-style="western"><surname>Molden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shafiei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>D.</given-names></name></person-group><article-title>Quetiapine Poisoning&#8212;Epidemiology, Toxicokinetics and Review of the Literature</article-title><source>LOJ Med. Sci.</source><year>2021</year><volume>5</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.32474/LOJMS.2021.05.000224</pub-id></element-citation></ref><ref id="B55-jox-14-00085"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baptist</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bannink</surname><given-names>M.</given-names></name></person-group><article-title>Delier als late complicatie van intoxicatie met quetiapine</article-title><source>Tijdschr. Psychiatr.</source><year>2018</year><volume>60</volume><fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">30132584</pub-id></element-citation></ref><ref id="B56-jox-14-00085"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hantson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>P.</given-names></name></person-group><article-title>Toxicokinetic Interaction Between Quetiapine and Antiretroviral Therapy Following Quetiapine Overdose</article-title><source>Drug Metab. Lett.</source><year>2010</year><volume>4</volume><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2174/187231210790980426</pub-id><pub-id pub-id-type="pmid">20201782</pub-id></element-citation></ref><ref id="B57-jox-14-00085"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grimm</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Richtand</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Stams</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Reele</surname><given-names>S.B.</given-names></name></person-group><article-title>Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics</article-title><source>Br. J. Clin. Pharmacol.</source><year>2006</year><volume>61</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02507.x</pub-id><pub-id pub-id-type="pmid">16390352</pub-id><pub-id pub-id-type="pmcid">PMC1884989</pub-id></element-citation></ref><ref id="B58-jox-14-00085"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yam</surname><given-names>M.F.C.</given-names></name><name name-style="western"><surname>Kiew</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>C.P.</given-names></name></person-group><article-title>Hyperglycemia and late onset seizures associated with quetiapine overdose</article-title><source>Tzu Chi Med. J.</source><year>2013</year><volume>25</volume><fpage>119</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.tcmj.2012.10.002</pub-id></element-citation></ref><ref id="B59-jox-14-00085"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>Y.W.J.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thyrum</surname><given-names>P.T.</given-names></name></person-group><article-title>The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine</article-title><source>J. Clin. Psychopharmacol.</source><year>2001</year><volume>21</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/00004714-200102000-00016</pub-id><pub-id pub-id-type="pmid">11199955</pub-id></element-citation></ref><ref id="B60-jox-14-00085"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vignali</surname><given-names>C.</given-names></name><name name-style="western"><surname>Freni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siodambro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Groppi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Osculati</surname><given-names>A.M.M.</given-names></name><name name-style="western"><surname>Morini</surname><given-names>L.</given-names></name></person-group><article-title>Distribution of quetiapine and metabolites in biological fluids and tissues</article-title><source>Forensic Sci. Int.</source><year>2020</year><volume>307</volume><fpage>110108</fpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2019.110108</pub-id><pub-id pub-id-type="pmid">31877542</pub-id></element-citation></ref><ref id="B61-jox-14-00085"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badhan</surname><given-names>R.K.S.</given-names></name><name name-style="western"><surname>Macfarlane</surname><given-names>H.</given-names></name></person-group><article-title>Quetiapine dose optimisation during gestation: A pharmacokinetic modelling study</article-title><source>J. Pharm. Pharmacol.</source><year>2020</year><volume>72</volume><fpage>670</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1111/jphp.13236</pub-id><pub-id pub-id-type="pmid">32012278</pub-id></element-citation></ref><ref id="B62-jox-14-00085"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>Relationship between serum concentration and clinical response of quetiapine in adolescents and adults with bipolar disorders in acute stage: A prospective observational study</article-title><source>J. Affect. Disord.</source><year>2023</year><volume>324</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2022.12.107</pub-id><pub-id pub-id-type="pmid">36586603</pub-id></element-citation></ref><ref id="B63-jox-14-00085"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gladden</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>McGlone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>F.</given-names></name></person-group><article-title>Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines&#8212;38 States and the District of Columbia, 2019&#8211;2020</article-title><source>Morb. Mortal Wkly. Rep.</source><year>2021</year><volume>70</volume><fpage>1136</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7034a2</pub-id><pub-id pub-id-type="pmid">34437522</pub-id><pub-id pub-id-type="pmcid">PMC8389388</pub-id></element-citation></ref><ref id="B64-jox-14-00085"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasselstr&#248;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Linnet</surname><given-names>K.</given-names></name></person-group><article-title>Quetiapine serum concentrations in psychiatric patients: The influence of comedication</article-title><source>Ther. Drug Monit.</source><year>2004</year><volume>26</volume><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1097/00007691-200410000-00005</pub-id><pub-id pub-id-type="pmid">15385830</pub-id></element-citation></ref><ref id="B65-jox-14-00085"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castberg</surname><given-names>I.</given-names></name><name name-style="western"><surname>Skogvoll</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spigset</surname><given-names>O.</given-names></name></person-group><article-title>Pharmacokinetics of quetiapine: Evidence from a routine therapeutic drug monitoring service</article-title><source>Eur. Neuropsychopharmacol.</source><year>2006</year><volume>16</volume><fpage>S444</fpage><pub-id pub-id-type="doi">10.1016/S0924-977X(06)70574-0</pub-id></element-citation></ref><ref id="B66-jox-14-00085"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauri</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Volonteri</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Fiorentini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bareggi</surname><given-names>S.R.</given-names></name></person-group><article-title>Two weeks&#8217; quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: A naturalistic study with drug plasma levels</article-title><source>Expert. Opin. Pharmacother.</source><year>2007</year><volume>8</volume><fpage>2207</fpage><lpage>2213</lpage><pub-id pub-id-type="doi">10.1517/14656566.8.14.2207</pub-id><pub-id pub-id-type="pmid">17927477</pub-id></element-citation></ref><ref id="B67-jox-14-00085"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaskiw</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Thyrum</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Arvanitis</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C.</given-names></name></person-group><article-title>Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders</article-title><source>Clin. Pharmacokinet.</source><year>2004</year><volume>43</volume><fpage>1025</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.2165/00003088-200443140-00005</pub-id><pub-id pub-id-type="pmid">15530131</pub-id></element-citation></ref><ref id="B68-jox-14-00085"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albantakis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Egberts</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mehler-Wex</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taurines</surname><given-names>R.</given-names></name><name name-style="western"><surname>Unterecker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wevetzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Romanos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>M.</given-names></name></person-group><article-title>Relationship between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders</article-title><source>Pharmacopsychiatry</source><year>2017</year><volume>50</volume><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1055/s-0043-109695</pub-id><pub-id pub-id-type="pmid">28561203</pub-id></element-citation></ref><ref id="B69-jox-14-00085"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flammia</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Valouch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Venuti</surname><given-names>S.</given-names></name></person-group><article-title>Tissue distribution of quetiapine in 20 cases in Virginia</article-title><source>J. Anal. Toxicol.</source><year>2006</year><volume>30</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1093/jat/30.4.287</pub-id><pub-id pub-id-type="pmid">16803670</pub-id></element-citation></ref><ref id="B70-jox-14-00085"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Mu&#241;oz</surname><given-names>F.</given-names></name><name name-style="western"><surname>&#193;lamo</surname><given-names>C.</given-names></name></person-group><article-title>Active metabolites as antidepressant drugs: The role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders</article-title><source>Front. Psychiatry</source><year>2013</year><volume>4</volume><elocation-id>48288</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2013.00102</pub-id><pub-id pub-id-type="pmcid">PMC3770982</pub-id><pub-id pub-id-type="pmid">24062697</pub-id></element-citation></ref><ref id="B71-jox-14-00085"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beelen</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>K.T.J.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>L.D.</given-names></name></person-group><article-title>Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone</article-title><source>Hum. Exp. Toxicol.</source><year>2001</year><volume>20</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1191/096032701678766778</pub-id><pub-id pub-id-type="pmid">11393275</pub-id></element-citation></ref><ref id="B72-jox-14-00085"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catalano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Catalano</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Agustines</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Paperwalla</surname><given-names>K.N.</given-names></name></person-group><article-title>Pediatric Quetiapine Overdose: A Case Report and Literature Review</article-title><source>J. Child. Adolesc. Psychopharmacol.</source><year>2002</year><volume>12</volume><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1089/104454602762599916</pub-id><pub-id pub-id-type="pmid">12625997</pub-id></element-citation></ref><ref id="B73-jox-14-00085"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McConville</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Arvanitis</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Thyrum</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Chaney</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Sorter</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Pharmacokinetics, Tolerability, and Clinical Effectiveness of Quetiapine Fumarate: An Open-Label Trial in Adolescents With Psychotic Disorders</article-title><source>J. Clin. Psychiatry</source><year>2000</year><volume>61</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.4088/JCP.v61n0403</pub-id><pub-id pub-id-type="pmid">10830145</pub-id></element-citation></ref><ref id="B74-jox-14-00085"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pascal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Guillen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pupo-Guillen</surname><given-names>M.</given-names></name></person-group><article-title>A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents</article-title><source>J. Child. Adolesc. Psychopharmacol.</source><year>2004</year><volume>11</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1089/104454601317261591</pub-id><pub-id pub-id-type="pmid">11838824</pub-id></element-citation></ref><ref id="B75-jox-14-00085"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Twaites</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Wilton</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Shakir</surname><given-names>S.A.W.</given-names></name></person-group><article-title>The safety of quetiapine: Results of a post-marketing surveillance study on 1728 patients in England</article-title><source>J. Psychopharmacol.</source><year>2007</year><volume>21</volume><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1177/0269881107073257</pub-id><pub-id pub-id-type="pmid">17656426</pub-id></element-citation></ref><ref id="B76-jox-14-00085"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furst</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Champion</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Pierre</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wirshing</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wirshing</surname><given-names>W.C.</given-names></name></person-group><article-title>Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin</article-title><source>Biol. Psychiatry</source><year>2002</year><volume>51</volume><fpage>264</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(01)01333-6</pub-id><pub-id pub-id-type="pmid">11839370</pub-id></element-citation></ref><ref id="B77-jox-14-00085"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.Y.</given-names></name></person-group><article-title>A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers</article-title><source>Int. Clin. Psychopharmacol.</source><year>2016</year><volume>31</volume><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1097/YIC.0000000000000124</pub-id><pub-id pub-id-type="pmid">26950553</pub-id></element-citation></ref><ref id="B78-jox-14-00085"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reilly</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Ayis</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ferrier</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.H.L.</given-names></name></person-group><article-title>QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1048</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02035-3</pub-id><pub-id pub-id-type="pmid">10744090</pub-id></element-citation></ref><ref id="B79-jox-14-00085"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddad</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>I.M.</given-names></name></person-group><article-title>Antipsychotic-related QTc prolongation, torsade de pointes and sudden death</article-title><source>Drugs</source><year>2002</year><volume>62</volume><fpage>1649</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.2165/00003495-200262110-00006</pub-id><pub-id pub-id-type="pmid">12109926</pub-id></element-citation></ref><ref id="B80-jox-14-00085"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Gaaly</surname><given-names>S.</given-names></name><name name-style="western"><surname>St John</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dunsmore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.M.</given-names></name></person-group><article-title>Atypical Neuroleptic Malignant Syndrome With Quetiapine: A Case Report and Review of the Literature</article-title><source>J. Clin. Psychopharmacol.</source><year>2009</year><volume>29</volume><fpage>497</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e3181b4b091</pub-id><pub-id pub-id-type="pmid">19745653</pub-id></element-citation></ref><ref id="B81-jox-14-00085"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belvederi Murri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guaglianone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bugliani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calcagno</surname><given-names>P.</given-names></name><name name-style="western"><surname>Respino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Innamorati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pompili</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amore</surname><given-names>M.</given-names></name></person-group><article-title>Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis</article-title><source>Drugs R. D</source><year>2015</year><volume>15</volume><fpage>45</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s40268-014-0078-0</pub-id><pub-id pub-id-type="pmid">25578944</pub-id><pub-id pub-id-type="pmcid">PMC4359181</pub-id></element-citation></ref><ref id="B82-jox-14-00085"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detweiler</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Detweiler</surname><given-names>J.G.</given-names></name></person-group><article-title>Case reports of neuroleptic malignant syndrome in context of quetiapine use</article-title><source>Psychiatr. Q</source><year>2013</year><volume>84</volume><fpage>523</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1007/s11126-013-9264-4</pub-id><pub-id pub-id-type="pmid">23686527</pub-id></element-citation></ref><ref id="B83-jox-14-00085"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiou</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.L.</given-names></name></person-group><article-title>A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review</article-title><source>Medicine</source><year>2015</year><volume>94</volume><fpage>e1752</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000001752</pub-id><pub-id pub-id-type="pmid">26512569</pub-id><pub-id pub-id-type="pmcid">PMC4985383</pub-id></element-citation></ref><ref id="B84-jox-14-00085"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demir</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Demir</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Yaylaci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tayci</surname><given-names>I.</given-names></name><name name-style="western"><surname>Baydar</surname><given-names>M.</given-names></name></person-group><article-title>Neuroleptic malignant syndrome induced by concomitant use of risperidone and quetiapine</article-title><source>Chrismed J. Heal. Res.</source><year>2016</year><volume>3</volume><fpage>141</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.4103/2348-3334.177643</pub-id></element-citation></ref><ref id="B85-jox-14-00085"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giuntoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dalmastri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cilloni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Orsi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stalteri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Demelas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giuliani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gordini</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Ponti</surname><given-names>F.</given-names></name><name name-style="western"><surname>La Manna</surname><given-names>G.</given-names></name></person-group><article-title>Severe quetiapine voluntary overdose successfully treated with a new hemoperfusion sorbent</article-title><source>Int. J. Artif. Organs</source><year>2019</year><volume>42</volume><fpage>516</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1177/0391398819837686</pub-id><pub-id pub-id-type="pmid">31006356</pub-id></element-citation></ref><ref id="B86-jox-14-00085"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lippmann</surname><given-names>S.</given-names></name></person-group><article-title>Blood Dyscrasia With Quetiapine and Ziprasidone</article-title><source>Psychosomatics</source><year>2005</year><volume>46</volume><fpage>89</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1176/appi.psy.46.1.89</pub-id><pub-id pub-id-type="pmid">15765830</pub-id></element-citation></ref><ref id="B87-jox-14-00085"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shpaner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ankoma-Sey</surname><given-names>V.</given-names></name><name name-style="western"><surname>Botero</surname><given-names>R.C.</given-names></name></person-group><article-title>Drug-induced liver injury: Hepatotoxicity of quetiapine revisited</article-title><source>Eur. J. Gastroenterol. Hepatol.</source><year>2008</year><volume>20</volume><fpage>1106</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e3282f8e3a0</pub-id><pub-id pub-id-type="pmid">19047843</pub-id></element-citation></ref><ref id="B88-jox-14-00085"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naharci</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Karadurmus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Demir</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bozoglu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doruk</surname><given-names>H.</given-names></name></person-group><article-title>Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine</article-title><source>Am. J. Psychiatry</source><year>2011</year><volume>168</volume><fpage>212</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2010.10091292</pub-id><pub-id pub-id-type="pmid">21297052</pub-id></element-citation></ref><ref id="B89-jox-14-00085"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>F.</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>E.</given-names></name><name name-style="western"><surname>Murta</surname><given-names>I.</given-names></name></person-group><article-title>Delirium induced by quetiapine and the potential role of norquetiapine</article-title><source>Front. Neurosci.</source><year>2019</year><volume>13</volume><elocation-id>886</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2019.00886</pub-id><pub-id pub-id-type="pmid">31481872</pub-id><pub-id pub-id-type="pmcid">PMC6710379</pub-id></element-citation></ref><ref id="B90-jox-14-00085"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Rodriguiz</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Wetsel</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B.L.</given-names></name></person-group><article-title>N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine&#8217;s Antidepressant Activity</article-title><source>Neuropsychopharmacol.</source><year>2008</year><volume>33</volume><fpage>2303</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301646</pub-id><pub-id pub-id-type="pmid">18059438</pub-id></element-citation></ref><ref id="B91-jox-14-00085"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crombez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Den Wijngaert</surname><given-names>V.</given-names></name><name name-style="western"><surname>Demyttenaere</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Fruyt</surname><given-names>J.</given-names></name></person-group><article-title>Delier ten gevolge van intoxicatie met quetiapine: Een systematisch literatuuronderzoek</article-title><source>Tijdschr. Psychiatr.</source><year>2020</year><volume>62</volume><fpage>358</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">32484564</pub-id></element-citation></ref><ref id="B92-jox-14-00085"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabre</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Arvanitis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pultz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Malick</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Slotnick</surname><given-names>V.B.</given-names></name></person-group><article-title>ICI 204,636, a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia</article-title><source>Clin. Ther.</source><year>1995</year><volume>17</volume><fpage>366</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/0149-2918(95)80102-2</pub-id><pub-id pub-id-type="pmid">7585841</pub-id></element-citation></ref><ref id="B93-jox-14-00085"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragicevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sachse</surname><given-names>J.</given-names></name><name name-style="western"><surname>H&#228;rtter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiemke</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.J.</given-names></name></person-group><article-title>Serum Concentrations of Quetiapine and Clinical Effects</article-title><source>Pharmacopsychiatry</source><year>2005</year><volume>38</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1055/s-2005-862636</pub-id></element-citation></ref><ref id="B94-jox-14-00085"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragicevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trotzauer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hiemke</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.J.</given-names></name></person-group><article-title>Gender and age effects on quetiapine serum concentrations in patients with schizophrenia or schizoaffective disorders</article-title><source>Pharmacopsychiatry</source><year>2005</year><volume>38</volume><fpage>A044</fpage><pub-id pub-id-type="doi">10.1055/s-2005-918666</pub-id></element-citation></ref><ref id="B95-jox-14-00085"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragicevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sachse</surname><given-names>J.</given-names></name><name name-style="western"><surname>H&#228;rtter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiemke</surname><given-names>C.</given-names></name></person-group><article-title>Therapeutic drug monitoring (TDM) of quetiapine</article-title><source>Pharmacopsychiatry</source><year>2003</year><volume>36</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1055/s-2003-825309</pub-id></element-citation></ref><ref id="B96-jox-14-00085"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerlach</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#252;nnerkopf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rothenh&#246;fer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Libal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Fegert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wewetzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mehler-Wex</surname><given-names>C.</given-names></name></person-group><article-title>Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders</article-title><source>Pharmacopsychiatry</source><year>2007</year><volume>40</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1055/s-2007-972573</pub-id><pub-id pub-id-type="pmid">17447177</pub-id></element-citation></ref><ref id="B97-jox-14-00085"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cobaugh</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Booze</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Scharman</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Manoguerra</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Caravati</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Chyka</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Woolf</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>L.S.</given-names></name><etal/></person-group><article-title>Atypical antipsychotic medication poisoning: An evidence-based consensus guideline for out-of-hospital management</article-title><source>Clin. Toxicol.</source><year>2008</year><volume>45</volume><fpage>918</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1080/15563650701665142</pub-id><pub-id pub-id-type="pmid">18163235</pub-id></element-citation></ref><ref id="B98-jox-14-00085"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aichhorn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Marksteiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zernig</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saria</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kemmler</surname><given-names>G.</given-names></name></person-group><article-title>Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations</article-title><source>Int. Clin. Psychopharmacol.</source><year>2006</year><volume>21</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1097/01.yic.0000188213.46667.f1</pub-id><pub-id pub-id-type="pmid">16421458</pub-id></element-citation></ref><ref id="B99-jox-14-00085"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagy</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy, safety and tolerability of quetiapine: Short-term high doses with long-term follow-up</article-title><source>Int. J. Psychiatry Clin. Pract.</source><year>2005</year><volume>9</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/13651500510014765</pub-id><pub-id pub-id-type="pmid">24945332</pub-id></element-citation></ref><ref id="B100-jox-14-00085"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sotiriou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Day</surname><given-names>R.O.</given-names></name></person-group><article-title>Restarting antidepressant and antipsychotic medication after intentional overdoses: Need for evidence-based guidance</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2019</year><volume>9</volume><fpage>2045125319836889</fpage><pub-id pub-id-type="doi">10.1177/2045125319836889</pub-id><pub-id pub-id-type="pmid">30956788</pub-id><pub-id pub-id-type="pmcid">PMC6444415</pub-id></element-citation></ref><ref id="B101-jox-14-00085"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwersen-Bergmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andresen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmoldt</surname><given-names>A.</given-names></name></person-group><article-title>Therapeutic and toxic blood concentrations of nearly 1000 drugs and other xenobiotics</article-title><source>Crit. Care</source><year>2012</year><volume>16</volume><fpage>R136</fpage><pub-id pub-id-type="doi">10.1186/cc11441</pub-id><pub-id pub-id-type="pmid">22835221</pub-id><pub-id pub-id-type="pmcid">PMC3580721</pub-id></element-citation></ref><ref id="B102-jox-14-00085"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Aboo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A.</given-names></name></person-group><article-title>Prolonged gastric emptying half-time and gastric hypomotility after drug overdose</article-title><source>Am. J. Emerg. Med.</source><year>2004</year><volume>22</volume><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2004.08.017</pub-id><pub-id pub-id-type="pmid">15666259</pub-id></element-citation></ref><ref id="B103-jox-14-00085"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>K.</given-names></name></person-group><article-title>Use of intravenous lipid emulsion in the resuscitation of a patient with cardiovascular collapse after a severe overdose of quetiapine</article-title><source>Clin. Toxicol.</source><year>2013</year><volume>51</volume><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.3109/15563650.2013.803229</pub-id><pub-id pub-id-type="pmid">23768031</pub-id></element-citation></ref><ref id="B104-jox-14-00085"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauber-L&#252;thy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Bodmer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Kupferschmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ceschi</surname><given-names>A.</given-names></name></person-group><article-title>Gastric pharmacobezoars in quetiapine extended-release overdose: A case series</article-title><source>Clin. Toxicol.</source><year>2013</year><volume>51</volume><fpage>937</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.3109/15563650.2013.856442</pub-id><pub-id pub-id-type="pmid">24199644</pub-id></element-citation></ref><ref id="B105-jox-14-00085"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceschi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rauber-Luthy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bodmer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kupferschmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>K.E.</given-names></name></person-group><article-title>Gastric pharmacobezoars in quetiapine overdose: A case series</article-title><source>Clin. Toxicol.</source><year>2011</year><volume>49</volume><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/15563650.2013.856442</pub-id><pub-id pub-id-type="pmid">24199644</pub-id></element-citation></ref><ref id="B106-jox-14-00085"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodmer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burkard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Beyrau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haschke</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose</article-title><source>Ther. Drug Monit.</source><year>2008</year><volume>30</volume><fpage>553</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e31817fd5ed</pub-id><pub-id pub-id-type="pmid">18641548</pub-id></element-citation></ref><ref id="B107-jox-14-00085"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoegberg</surname><given-names>L.C.G.</given-names></name><name name-style="western"><surname>Refsgaard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Personne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Panagiotidis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Studsgaard Petersen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Annas</surname><given-names>A.</given-names></name></person-group><article-title>Potential pharmacobezoar formation of large size extended-release tablets and their dissolution&#8211;an in vitro study</article-title><source>Clin. Toxicol.</source><year>2019</year><volume>57</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1080/15563650.2018.1513138</pub-id><pub-id pub-id-type="pmid">30306811</pub-id></element-citation></ref><ref id="B108-jox-14-00085"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruha</surname><given-names>A.M.</given-names></name></person-group><article-title>Overdose of atypical antipsychotics: Clinical presentation, mechanisms of toxicity and management</article-title><source>CNS Drugs</source><year>2012</year><volume>26</volume><fpage>601</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.2165/11631640-000000000-00000</pub-id><pub-id pub-id-type="pmid">22668123</pub-id></element-citation></ref><ref id="B109-jox-14-00085"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minns</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.F.</given-names></name></person-group><article-title>Toxicology and overdose of atypical antipsychotics</article-title><source>J. Emerg. Med.</source><year>2012</year><volume>43</volume><fpage>906</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2012.03.002</pub-id><pub-id pub-id-type="pmid">22555052</pub-id></element-citation></ref><ref id="B110-jox-14-00085"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>M.J.</given-names></name></person-group><article-title>The pharmacology and toxicology of atypical antipsychotic agents</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2001</year><volume>39</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1081/CLT-100102873</pub-id><pub-id pub-id-type="pmid">11327216</pub-id></element-citation></ref><ref id="B111-jox-14-00085"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isbister</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Duffull</surname><given-names>S.B.</given-names></name></person-group><article-title>Quetiapine overdose: Predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal</article-title><source>Int. Clin. Psychopharmacol.</source><year>2009</year><volume>24</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1097/YIC.0b013e32832bb078</pub-id><pub-id pub-id-type="pmid">19494786</pub-id></element-citation></ref><ref id="B112-jox-14-00085"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trenton</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Currier</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Zwemer</surname><given-names>F.L.</given-names></name></person-group><article-title>Fatalities associated with therapeutic use and overdose of atypical antipsychotics</article-title><source>CNS Drugs</source><year>2003</year><volume>17</volume><fpage>307</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.2165/00023210-200317050-00002</pub-id><pub-id pub-id-type="pmid">12665390</pub-id></element-citation></ref><ref id="B113-jox-14-00085"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mowry</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanftleben</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name></person-group><article-title>Eighteen month retrospective evaluation of Seroquel(R) exposures</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>1999</year><volume>37</volume><fpage>631</fpage></element-citation></ref><ref id="B114-jox-14-00085"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luhr</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sj&#246;berg</surname><given-names>G.</given-names></name></person-group><article-title>Acute Quetiapine Overdose in Adults&#8212;Experience in Sweden</article-title><source>Clin. Toxicol.</source><year>2011</year><volume>49</volume><fpage>267</fpage><lpage>268</lpage></element-citation></ref><ref id="B115-jox-14-00085"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillay-Fuentes Lorente</surname><given-names>V.</given-names></name><name name-style="western"><surname>van Rensburg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cloete</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lahri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Decloedt</surname><given-names>E.H.</given-names></name></person-group><article-title>Vasopressor therapy in atypical antipsychotic overdose</article-title><source>S. Afr. Med. J.</source><year>2020</year><volume>110</volume><fpage>1003</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.7196/SAMJ.2020.v110i10.14771</pub-id><pub-id pub-id-type="pmid">33205729</pub-id></element-citation></ref><ref id="B116-jox-14-00085"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Stellpflug</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ellsworth</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>C.R.</given-names></name></person-group><article-title>Reversal of quetiapine-induced altered mental status with physostigmine: A case series</article-title><source>Am. J. Emerg. Med.</source><year>2012</year><volume>30</volume><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2011.05.015</pub-id><pub-id pub-id-type="pmid">21802878</pub-id></element-citation></ref><ref id="B117-jox-14-00085"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Monnet-Tschudi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kupferschmidt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ceschi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rauber-L&#252;thy</surname><given-names>C.</given-names></name></person-group><article-title>Seizures after single-agent overdose with pharmaceutical drugs: Analysis of cases reported to a poison center</article-title><source>Clin. Toxicol.</source><year>2014</year><volume>52</volume><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.3109/15563650.2014.918627</pub-id><pub-id pub-id-type="pmid">24844578</pub-id></element-citation></ref><ref id="B118-jox-14-00085"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mainio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuusisto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hakko</surname><given-names>H.</given-names></name><name name-style="western"><surname>Riipinen</surname><given-names>P.</given-names></name></person-group><article-title>Antipsychotics as a method of suicide: Population based follow-up study of suicide in Northern Finland</article-title><source>Nord. J. Psychiatry</source><year>2021</year><volume>75</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1080/08039488.2020.1847323</pub-id><pub-id pub-id-type="pmid">33215967</pub-id></element-citation></ref><ref id="B119-jox-14-00085"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name></person-group><article-title>Morbidity and mortality associated with medications used in the treatment of depression: An analysis of cases reported to U.S. poison control centers, 2000-2014</article-title><source>Am. J. Psychiatry</source><year>2017</year><volume>174</volume><fpage>438</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2016.16050523</pub-id><pub-id pub-id-type="pmid">28135844</pub-id></element-citation></ref><ref id="B120-jox-14-00085"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiihonen</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#246;nnqvist</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wahlbeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klaukka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Niskanen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haukka</surname><given-names>J.</given-names></name></person-group><article-title>Articles 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study)</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>620</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60742-X</pub-id><pub-id pub-id-type="pmid">19595447</pub-id></element-citation></ref><ref id="B121-jox-14-00085"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffiths</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>R.J.</given-names></name></person-group><article-title>Fatal poisoning with antipsychotic drugs, England and Wales 1993-2002</article-title><source>J. Psychopharmacol.</source><year>2005</year><volume>19</volume><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1177/0269881105056658</pub-id><pub-id pub-id-type="pmid">16272190</pub-id></element-citation></ref><ref id="B122-jox-14-00085"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pilgrim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gerostamoulos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name></person-group><article-title>Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia</article-title><source>Drug Alcohol. Depend.</source><year>2018</year><volume>187</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.03.002</pub-id><pub-id pub-id-type="pmid">29655032</pub-id></element-citation></ref><ref id="B123-jox-14-00085"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Hoppe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heard</surname><given-names>K.</given-names></name></person-group><article-title>A systematic review of cardiovascular effects following atypical antipsychotic medication overdose</article-title><source>Am. J. Emerg. Med.</source><year>2009</year><volume>27</volume><fpage>607</fpage><pub-id pub-id-type="doi">10.1016/j.ajem.2008.04.020</pub-id><pub-id pub-id-type="pmid">19497468</pub-id><pub-id pub-id-type="pmcid">PMC2759317</pub-id></element-citation></ref><ref id="B124-jox-14-00085"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name></person-group><article-title>Quetiapine misuse and abuse: Is it an atypical paradigm of drug seeking behavior?</article-title><source>J. Res. Pharm. Pract.</source><year>2017</year><volume>6</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.4103/2279-042X.200987</pub-id><pub-id pub-id-type="pmid">28331860</pub-id><pub-id pub-id-type="pmcid">PMC5348850</pub-id></element-citation></ref><ref id="B125-jox-14-00085"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawkins</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Unwin</surname><given-names>P.</given-names></name></person-group><article-title>Paradoxical and severe hypotension in response to adrenaline infusions in massive quetiapine overdose</article-title><source>Crit. Care Resusc.</source><year>2008</year><volume>10</volume><fpage>320</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/S1441-2772(23)01893-8</pub-id><pub-id pub-id-type="pmid">19049484</pub-id></element-citation></ref><ref id="B126-jox-14-00085"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibiino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trappoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balzarro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Atti</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>de Ronchi</surname><given-names>D.</given-names></name></person-group><article-title>Coma after quetiapine fumarate intentional overdose in a 71-year-old man: A case report</article-title><source>Drug Saf. Case Rep.</source><year>2015</year><volume>2</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1007/s40800-015-0005-5</pub-id><pub-id pub-id-type="pmid">27747715</pub-id><pub-id pub-id-type="pmcid">PMC4982457</pub-id></element-citation></ref><ref id="B127-jox-14-00085"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.L.</given-names></name></person-group><article-title>Association Between Antipsychotic Agents and Risk of Acute Respiratory Failure in Patients With Chronic Obstructive Pulmonary Disease</article-title><source>JAMA Psychiatry</source><year>2017</year><volume>74</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.3793</pub-id><pub-id pub-id-type="pmid">28055066</pub-id></element-citation></ref><ref id="B128-jox-14-00085"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gomaa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cortez-Resendiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bellon</surname><given-names>A.</given-names></name></person-group><article-title>Quetiapine and Wolff-Parkinson-White Syndrome</article-title><source>Case Rep. Psychiatry</source><year>2020</year><volume>2020</volume><fpage>6633385</fpage><pub-id pub-id-type="doi">10.1155/2020/6633385</pub-id><pub-id pub-id-type="pmid">33381342</pub-id><pub-id pub-id-type="pmcid">PMC7748904</pub-id></element-citation></ref><ref id="B129-jox-14-00085"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>C.U.</given-names></name></person-group><article-title>Quetiapine and other antipsychotics combined with opioids in legal autopsy cases: A random finding or cause of fatal outcome?</article-title><source>Basic. Clin. Pharmacol. Toxicol.</source><year>2021</year><volume>128</volume><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/bcpt.13480</pub-id><pub-id pub-id-type="pmid">33245632</pub-id></element-citation></ref><ref id="B130-jox-14-00085"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calderone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Testai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martinotti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Del Tacca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Breschi</surname><given-names>M.C.</given-names></name></person-group><article-title>Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: The case of antipsychotics</article-title><source>J. Pharm. Pharmacol.</source><year>2010</year><volume>57</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1211/0022357055272</pub-id><pub-id pub-id-type="pmid">15720777</pub-id></element-citation></ref><ref id="B131-jox-14-00085"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campleman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Brent</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pizon</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wax</surname><given-names>P.</given-names></name><name name-style="western"><surname>Manini</surname><given-names>A.F.</given-names></name></person-group><article-title>Drug-specific risk of severe QT prolongation following acute drug overdose</article-title><source>Clin. Toxicol.</source><year>2020</year><volume>58</volume><fpage>1326</fpage><pub-id pub-id-type="doi">10.1080/15563650.2020.1746330</pub-id><pub-id pub-id-type="pmcid">PMC7541562</pub-id><pub-id pub-id-type="pmid">32252558</pub-id></element-citation></ref><ref id="B132-jox-14-00085"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasnain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vieweg</surname><given-names>W.V.R.</given-names></name><name name-style="western"><surname>Howland</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kogut</surname><given-names>C.</given-names></name><name name-style="western"><surname>Breden Crouse</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Koneru</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Hancox</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Digby</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Baranchuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Quetiapine, QTc interval prolongation, and torsade de pointes: A review of case reports</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2014</year><volume>4</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.1177/2045125313510194</pub-id><pub-id pub-id-type="pmid">25057346</pub-id><pub-id pub-id-type="pmcid">PMC4107702</pub-id></element-citation></ref><ref id="B133-jox-14-00085"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isbister</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.</given-names></name></person-group><article-title>Quetiapine overdose, good or bad, or just more of the same?</article-title><source>Clin. Toxicol.</source><year>2023</year><volume>61</volume><fpage>49</fpage></element-citation></ref><ref id="B134-jox-14-00085"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khaire</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Nagarajarao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Quin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Borganelli</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>R.C.</given-names></name></person-group><article-title>Electrocardiographic brugada pattern induced by quetiapine overdose</article-title><source>J. Investig. Med.</source><year>2012</year><volume>60</volume><fpage>322</fpage><lpage>323</lpage></element-citation></ref><ref id="B135-jox-14-00085"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lannemyr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>K.</given-names></name></person-group><article-title>Severe overdose of quetiapine treated successfully with extracorporeal life support</article-title><source>Clin. Toxicol.</source><year>2012</year><volume>50</volume><fpage>258</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.3109/15563650.2012.665456</pub-id><pub-id pub-id-type="pmid">22380463</pub-id></element-citation></ref><ref id="B136-jox-14-00085"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muschler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoyte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brent</surname><given-names>J.</given-names></name></person-group><article-title>The role of QRS complex prolongation in predicting severe toxicity in single-xenobiotic overdose</article-title><source>Clin. Toxicol.</source><year>2024</year><volume>62</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1080/15563650.2024.2307356</pub-id><pub-id pub-id-type="pmid">38329803</pub-id></element-citation></ref><ref id="B137-jox-14-00085"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Marcil</surname><given-names>W.A.</given-names></name></person-group><article-title>Death associated with quetiapine overdose</article-title><source>Am. J. Psychiatry</source><year>2002</year><volume>159</volume><fpage>2114</fpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.12.2114</pub-id><pub-id pub-id-type="pmid">12450973</pub-id></element-citation></ref><ref id="B138-jox-14-00085"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Unverferth</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>E.H.</given-names></name></person-group><article-title>Delayed-Onset Seizure in a Mild Quetiapine Overdose: Report of a Case and Review of the Literature</article-title><source>Case Rep. Psychiatry</source><year>2018</year><volume>2018</volume><fpage>7623051</fpage><pub-id pub-id-type="doi">10.1155/2018/7623051</pub-id><pub-id pub-id-type="pmid">29888020</pub-id><pub-id pub-id-type="pmcid">PMC5977051</pub-id></element-citation></ref><ref id="B139-jox-14-00085"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Wax</surname><given-names>P.M.</given-names></name></person-group><article-title>Late-onset seizures associated with quetiapine poisoning</article-title><source>J. Med. Toxicol.</source><year>2009</year><volume>5</volume><fpage>24</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/BF03160977</pub-id><pub-id pub-id-type="pmid">19191211</pub-id><pub-id pub-id-type="pmcid">PMC3550337</pub-id></element-citation></ref><ref id="B140-jox-14-00085"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barcelo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>C.</given-names></name><name name-style="western"><surname>Castanyer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Puiguriguer</surname><given-names>J.</given-names></name></person-group><article-title>Delayed seizures after topiramate, venlafaxine and quetiapine overdose</article-title><source>Med. Clin.</source><year>2010</year><volume>135</volume><fpage>191</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.medcli.2009.05.011</pub-id><pub-id pub-id-type="pmid">19647279</pub-id></element-citation></ref><ref id="B141-jox-14-00085"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strachan</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Benoff</surname><given-names>B.A.</given-names></name></person-group><article-title>Mental status change, myoclonus, electrocardiographic changes, and acute respiratory distress syndrome induced by quetiapine overdose</article-title><source>Pharmacotherapy</source><year>2006</year><volume>26</volume><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1592/phco.26.4.578</pub-id><pub-id pub-id-type="pmid">16553519</pub-id></element-citation></ref><ref id="B142-jox-14-00085"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dogu</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sevim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaleagasi</surname><given-names>H.S.</given-names></name></person-group><article-title>Seizures associated with quetiapine treatment</article-title><source>Ann. Pharmacother.</source><year>2003</year><volume>37</volume><fpage>1224</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1345/aph.1C516</pub-id><pub-id pub-id-type="pmid">12921503</pub-id></element-citation></ref><ref id="B143-jox-14-00085"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedges</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Jeppson</surname><given-names>K.G.</given-names></name></person-group><article-title>New-Onset Seizure Associated with Quetiapine and Olanzapine</article-title><source>Ann. Pharmacother.</source><year>2002</year><volume>36</volume><fpage>437</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1345/aph.1A207</pub-id><pub-id pub-id-type="pmid">11895056</pub-id></element-citation></ref><ref id="B144-jox-14-00085"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujisaki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ichiba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Namera</surname><given-names>A.</given-names></name></person-group><article-title>Refractory seizures due to severe quetiapine poisoning</article-title><source>Clin. Toxicol.</source><year>2023</year><volume>61</volume><fpage>620</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1080/15563650.2023.2251674</pub-id><pub-id pub-id-type="pmid">37655784</pub-id></element-citation></ref><ref id="B145-jox-14-00085"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fioravanti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cavallieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Macaluso</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Valzania</surname><given-names>F.</given-names></name></person-group><article-title>Subcortical generalized myoclonus as a presenting symptom of quetiapine overdose</article-title><source>Neurol. Sci.</source><year>2022</year><volume>43</volume><fpage>6135</fpage><pub-id pub-id-type="doi">10.1007/s10072-022-06174-w</pub-id><pub-id pub-id-type="pmid">35641732</pub-id><pub-id pub-id-type="pmcid">PMC9155232</pub-id></element-citation></ref><ref id="B146-jox-14-00085"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velayudhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kirchner</surname><given-names>V.</given-names></name></person-group><article-title>Quetiapine-induced myoclonus</article-title><source>Int. Clin. Psychopharmacol.</source><year>2005</year><volume>20</volume><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1097/00004850-200503000-00011</pub-id><pub-id pub-id-type="pmid">15729090</pub-id></element-citation></ref><ref id="B147-jox-14-00085"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiloha</surname><given-names>R.</given-names></name></person-group><article-title>Quetiapine induced myoclonus</article-title><source>Indian. J. Med. Sci.</source><year>2009</year><volume>62</volume><fpage>422</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.4103/0019-5359.44024</pub-id><pub-id pub-id-type="pmid">19008618</pub-id></element-citation></ref><ref id="B148-jox-14-00085"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fond</surname><given-names>G.</given-names></name><name name-style="western"><surname>MacGregor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ducasse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brittner</surname><given-names>M.</given-names></name></person-group><article-title>Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder</article-title><source>Psychiatry Res.</source><year>2014</year><volume>216</volume><fpage>286</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2014.01.049</pub-id><pub-id pub-id-type="pmid">24582773</pub-id></element-citation></ref><ref id="B149-jox-14-00085"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antia</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Sholevar</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D.A.</given-names></name></person-group><article-title>Overdoses and ingestions of second-generation antipsychotics in children and adolescents</article-title><source>J. Child. Adolesc. Psychopharmacol.</source><year>2005</year><volume>15</volume><fpage>970</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1089/cap.2005.15.970</pub-id><pub-id pub-id-type="pmid">16379518</pub-id></element-citation></ref><ref id="B150-jox-14-00085"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhyee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Pedapati</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name></person-group><article-title>Prolonged delirium after quetiapine overdose</article-title><source>Pediatr. Emerg. Care</source><year>2010</year><volume>26</volume><fpage>754</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1097/PEC.0b013e3181f39d5b</pub-id><pub-id pub-id-type="pmid">20930599</pub-id></element-citation></ref><ref id="B151-jox-14-00085"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miodownik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alkatnany</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frolova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>V.</given-names></name></person-group><article-title>Delirium associated with lithium-quetiapine combination</article-title><source>Clin. Neuropharmacol.</source><year>2008</year><volume>31</volume><fpage>176</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e31814a619d</pub-id><pub-id pub-id-type="pmid">18520985</pub-id></element-citation></ref><ref id="B152-jox-14-00085"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liolios</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sentissi</surname><given-names>O.</given-names></name></person-group><article-title>Rhabdomyolysis following Acute Extended-Release Quetiapine Poisoning: A Case Report</article-title><source>Case Rep. Psychiatry</source><year>2012</year><volume>2012</volume><fpage>347421</fpage><pub-id pub-id-type="doi">10.1155/2012/347421</pub-id><pub-id pub-id-type="pmid">23304601</pub-id><pub-id pub-id-type="pmcid">PMC3530860</pub-id></element-citation></ref><ref id="B153-jox-14-00085"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickmann</surname><given-names>J.R.M.</given-names></name><name name-style="western"><surname>Dickmann</surname><given-names>L.M.</given-names></name></person-group><article-title>An uncommonly recognized cause of rhabdomyolysis after quetiapine intoxication</article-title><source>Am. J. Emerg. Med.</source><year>2010</year><volume>28</volume><fpage>1060.e1</fpage><lpage>1060.e2</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2010.01.025</pub-id><pub-id pub-id-type="pmid">20825857</pub-id></element-citation></ref><ref id="B154-jox-14-00085"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Puckett</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>R.L.</given-names></name></person-group><article-title>Quetiapine overdose and severe rhabdomyolysis</article-title><source>J. Clin. Psychopharmacol.</source><year>2004</year><volume>24</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.1097/01.jcp.0000126663.04153.3f</pub-id><pub-id pub-id-type="pmid">15118490</pub-id></element-citation></ref><ref id="B155-jox-14-00085"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Marotta</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Goteti</surname><given-names>R.</given-names></name></person-group><article-title>Atypical Neuroleptic Malignant Syndrome in the Setting of Quetiapine Overdose: A Case Report and Review of the Literature</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e12602</fpage><pub-id pub-id-type="doi">10.7759/cureus.12602</pub-id><pub-id pub-id-type="pmid">33585092</pub-id><pub-id pub-id-type="pmcid">PMC7872006</pub-id></element-citation></ref><ref id="B156-jox-14-00085"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pr&#233;court</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dunewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>G.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.R.</given-names></name></person-group><article-title>Multiple Complications and Withdrawal Syndrome Associated with Quetiapine/Venlafaxine Intoxication</article-title><source>Ann. Pharmacother.</source><year>2005</year><volume>39</volume><fpage>153</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1345/aph.1E073</pub-id><pub-id pub-id-type="pmid">15562144</pub-id></element-citation></ref><ref id="B157-jox-14-00085"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nin&#269;evi&#263;</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Lasi&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Glavina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mika&#269;i&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carev</surname><given-names>M.</given-names></name><name name-style="western"><surname>Podrug</surname><given-names>K.</given-names></name></person-group><article-title>Quetiapine poisoning associated with neuroleptic malignant syndrome, rhabdomyolysis and renal failure: A case report</article-title><source>Psychiatr. Danub.</source><year>2017</year><volume>29</volume><fpage>84</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.24869/psyd.2017.84</pub-id><pub-id pub-id-type="pmid">28291979</pub-id></element-citation></ref><ref id="B158-jox-14-00085"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;z&#231;el&#305;k Ero&#287;lu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>M.&#304;.</given-names></name><name name-style="western"><surname>Yazici</surname><given-names>M.K.</given-names></name></person-group><article-title>Atypical neuroleptic malignant syndrome induced by low dose quetiapine in a patient treated with donepezil</article-title><source>Noropsikiyatri Ars.</source><year>2021</year><volume>58</volume><fpage>166</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.29399/npa.27421</pub-id><pub-id pub-id-type="pmcid">PMC8214739</pub-id><pub-id pub-id-type="pmid">34188601</pub-id></element-citation></ref><ref id="B159-jox-14-00085"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schattner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kitroser</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.D.</given-names></name></person-group><article-title>Fatal Neuroleptic Malignant Syndrome Associated With Quetiapine</article-title><source>Am. J. Ther.</source><year>2016</year><volume>23</volume><fpage>e1209</fpage><lpage>e1210</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000000274</pub-id><pub-id pub-id-type="pmid">26132604</pub-id></element-citation></ref><ref id="B160-jox-14-00085"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nestor</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>R.</given-names></name></person-group><article-title>Neuroleptic Malignant Syndrome Secondary to Quetiapine in Critical Care: A Case Report</article-title><source>A&amp;A Pract.</source><year>2020</year><volume>14</volume><fpage>e01318</fpage><pub-id pub-id-type="doi">10.1213/XAA.0000000000001318</pub-id><pub-id pub-id-type="pmid">32985851</pub-id></element-citation></ref><ref id="B161-jox-14-00085"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sing</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Ramaekers</surname><given-names>G.M.G.I.</given-names></name><name name-style="western"><surname>Van Harten</surname><given-names>P.N.</given-names></name></person-group><article-title>Neuroleptic malignant syndrome and quetiapine</article-title><source>Am. J. Psychiatry</source><year>2002</year><volume>159</volume><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.1.149</pub-id><pub-id pub-id-type="pmid">11772710</pub-id></element-citation></ref><ref id="B162-jox-14-00085"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>D.C.L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.N.</given-names></name></person-group><article-title>Atypical neuroleptic malignant syndrome precipitated by clozapine and quetiapine overdose: A diagnostic challenge</article-title><source>Innov. Clin. Neurosci.</source><year>2018</year><volume>15</volume><fpage>20</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">30254795</pub-id><pub-id pub-id-type="pmcid">PMC6145603</pub-id></element-citation></ref><ref id="B163-jox-14-00085"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filkins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kiernan</surname><given-names>E.</given-names></name></person-group><article-title>An atypical use of MDAC: Enhanced elimination of quetiapine in a massive overdose</article-title><source>Clin. Toxicol.</source><year>2021</year><volume>59</volume><fpage>1057</fpage></element-citation></ref><ref id="B164-jox-14-00085"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenzel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruhnau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Einwaechter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Felgenhauer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Romaneck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pfab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eyer</surname><given-names>F.</given-names></name></person-group><article-title>Gastroscopic bezoar removal in acute quetiapine poisoning</article-title><source>Clin. Toxicol.</source><year>2013</year><volume>51</volume><fpage>317</fpage><lpage>318</lpage></element-citation></ref><ref id="B165-jox-14-00085"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kielstein</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ghannoum</surname><given-names>M.</given-names></name></person-group><article-title>Letter to the editor concerning the case report &#8220;Successful treatment of severe quetiapine intoxication with CytoSorb hemoadsorption&#8221;</article-title><source>J. Clin. Pharm. Ther.</source><year>2022</year><volume>47</volume><fpage>1493</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1111/jcpt.13749</pub-id><pub-id pub-id-type="pmid">35919960</pub-id></element-citation></ref><ref id="B166-jox-14-00085"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Namera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>Y.</given-names></name></person-group><article-title>Comparison of serum and whole blood concentrations in quetiapine overdose cases</article-title><source>Forensic Toxicol.</source><year>2022</year><volume>40</volume><fpage>403</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s11419-022-00618-w</pub-id><pub-id pub-id-type="pmid">36454407</pub-id></element-citation></ref><ref id="B167-jox-14-00085"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breivik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tunset</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Schou</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>J.</given-names></name></person-group><article-title>Distribution of quetiapine between serum and whole blood in therapeutic drug-monitoring specimens</article-title><source>J. Anal. Toxicol.</source><year>2024</year><volume>48</volume><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1093/jat/bkae006</pub-id><pub-id pub-id-type="pmid">38407283</pub-id><pub-id pub-id-type="pmcid">PMC10977622</pub-id></element-citation></ref><ref id="B168-jox-14-00085"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Van Schalkwyk</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Seedat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>R.J.</given-names></name></person-group><article-title>Plasma, oral fluid, and whole-blood distribution of antipsychotics and metabolites in clinical samples</article-title><source>Ther. Drug Monit.</source><year>2013</year><volume>35</volume><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e318283eaf2</pub-id><pub-id pub-id-type="pmid">23666566</pub-id></element-citation></ref><ref id="B169-jox-14-00085"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skov</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Linnet</surname><given-names>K.</given-names></name></person-group><article-title>Postmortem quetiapine reference concentrations in brain and blood</article-title><source>J. Anal. Toxicol.</source><year>2015</year><volume>39</volume><fpage>557</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/jat/bkv072</pub-id><pub-id pub-id-type="pmid">26159868</pub-id></element-citation></ref><ref id="B170-jox-14-00085"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntyre</surname><given-names>I.M.</given-names></name></person-group><article-title>Analytical data supporting the &#8220;theoretical&#8221; postmortem redistribution factor (Ft): A new model to evaluate postmortem redistribution</article-title><source>Forensic Sci. Res.</source><year>2016</year><volume>1</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1080/20961790.2016.1253255</pub-id><pub-id pub-id-type="pmid">30483608</pub-id><pub-id pub-id-type="pmcid">PMC6197142</pub-id></element-citation></ref><ref id="B171-jox-14-00085"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>K.L.</given-names></name></person-group><article-title>Quetiapine (Seroquel<sup>&#174;</sup>) concentrations in seven postmortem cases</article-title><source>J. Anal. Toxicol.</source><year>2000</year><volume>24</volume><fpage>300</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1093/jat/24.4.300</pub-id><pub-id pub-id-type="pmid">10872579</pub-id></element-citation></ref><ref id="B172-jox-14-00085"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelaal</surname><given-names>G.M.M.</given-names></name><name name-style="western"><surname>Hegazy</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Etewa</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Elmesallamy</surname><given-names>G.E.A.</given-names></name></person-group><article-title>Postmortem redistribution of drugs: A literature review</article-title><source>Forensic Sci. Med. Pathol.</source><year>2023</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s12024-023-00709-z</pub-id><pub-id pub-id-type="pmid">37715933</pub-id><pub-id pub-id-type="pmcid">PMC11790690</pub-id></element-citation></ref><ref id="B173-jox-14-00085"><label>173.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Maan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ershadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saadabadi</surname><given-names>A.</given-names></name></person-group><article-title>Quetiapine</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK459145/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK459145/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-10">(accessed on 10 October 2024)</date-in-citation><pub-id pub-id-type="pmid">29083706</pub-id></element-citation></ref><ref id="B174-jox-14-00085"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skov</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Linnet</surname><given-names>K.</given-names></name></person-group><article-title>Postmortem femoral blood reference concentrations of aripiprazole, chlorprothixene, and quetiapine</article-title><source>J. Anal. Toxicol.</source><year>2015</year><volume>39</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/jat/bku121</pub-id><pub-id pub-id-type="pmid">25342720</pub-id></element-citation></ref><ref id="B175-jox-14-00085"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hieger</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>N.E.</given-names></name></person-group><article-title>Lipid Emulsion Therapy for Quetiapine Overdose</article-title><source>Am. J. Ther.</source><year>2020</year><volume>27</volume><fpage>E518</fpage><lpage>E519</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000000969</pub-id><pub-id pub-id-type="pmid">32769389</pub-id></element-citation></ref><ref id="B176-jox-14-00085"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harmon</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Benitez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Krenzelok</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Cortes-Belen</surname><given-names>E.</given-names></name></person-group><article-title>Loss of consciousness from acute quetiapine overdosage</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>1998</year><volume>36</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.3109/15563659809028056</pub-id><pub-id pub-id-type="pmid">9776965</pub-id></element-citation></ref><ref id="B177-jox-14-00085"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>V.</given-names></name><name name-style="western"><surname>Farah</surname><given-names>N.</given-names></name></person-group><article-title>Quetiapine overdose</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2010</year><volume>44</volume><fpage>1144</fpage><pub-id pub-id-type="doi">10.3109/00048674.2010.518948</pub-id><pub-id pub-id-type="pmid">21070111</pub-id></element-citation></ref><ref id="B178-jox-14-00085"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watts</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wax</surname><given-names>P.</given-names></name></person-group><article-title>Physostigmine administration for quetiapine toxicity</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2003</year><volume>41</volume><fpage>646</fpage><lpage>647</lpage></element-citation></ref><ref id="B179-jox-14-00085"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>L.</given-names></name></person-group><article-title>Gift of the glob&#8212;Is it foolproof?</article-title><source>Anaesthesia</source><year>2009</year><volume>64</volume><fpage>1031</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.2009.06048.x</pub-id><pub-id pub-id-type="pmid">19686503</pub-id></element-citation></ref><ref id="B180-jox-14-00085"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mowry</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schauben</surname><given-names>J.L.</given-names></name></person-group><article-title>2015 Annual Report of the American Association of Poison Control Centers&#8217; National Poison Data System (NPDS): 33rd Annual Report</article-title><source>Clin. Toxicol.</source><year>2016</year><volume>54</volume><fpage>924</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1080/15563650.2016.1245421</pub-id><pub-id pub-id-type="pmid">28004588</pub-id></element-citation></ref><ref id="B181-jox-14-00085"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gummin</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Mowry</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Beuhler</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Bronstein</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Rivers</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>N.P.T.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>J.</given-names></name></person-group><article-title>2020 Annual Report of the American Association of Poison Control Centers&#8217; National Poison Data System (NPDS): 38th Annual Report</article-title><source>Clin. Toxicol.</source><year>2021</year><volume>59</volume><fpage>1282</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1080/15563650.2021.1989785</pub-id><pub-id pub-id-type="pmid">34890263</pub-id></element-citation></ref><ref id="B182-jox-14-00085"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vivek</surname><given-names>S.</given-names></name></person-group><article-title>No QT interval prolongation associated with quetiapine overdose</article-title><source>Am. J. Emerg. Med.</source><year>2004</year><volume>22</volume><fpage>330</fpage><pub-id pub-id-type="doi">10.1016/j.ajem.2004.04.025</pub-id><pub-id pub-id-type="pmid">15258889</pub-id></element-citation></ref><ref id="B183-jox-14-00085"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loftus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dewhirst</surname><given-names>W.</given-names></name><name name-style="western"><surname>Surgenor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koff</surname><given-names>M.</given-names></name></person-group><article-title>A Unique Presentation of Massive Quetiapine Overdose: Prolonged Anticholinergic Delirium and Acute Reversal with Physostigmine</article-title><source>Crit. Care Med.</source><year>2010</year><volume>38</volume><fpage>U277</fpage></element-citation></ref><ref id="B184-jox-14-00085"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gald&#243;s Barroso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ulla An&#233;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;nez Vicente</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arozemena Baquerizo</surname><given-names>J.</given-names></name></person-group><article-title>Intoxicaci&#243;n por quetiapina</article-title><source>Med. Clin.</source><year>2001</year><volume>117</volume><fpage>638</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/S0025-7753(01)72206-3</pub-id><pub-id pub-id-type="pmid">11714478</pub-id></element-citation></ref><ref id="B185-jox-14-00085"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubbard</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>House</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name></person-group><article-title>Low-dose lipid emulsion for pediatric vasoplegic shock due to quetiapine and fluvoxamine overdose: A case report</article-title><source>J. Emerg. Crit. Care Med.</source><year>2022</year><volume>6</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.21037/jeccm-22-53</pub-id></element-citation></ref><ref id="B186-jox-14-00085"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reuchsel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gonnert</surname><given-names>F.A.</given-names></name></person-group><article-title>Successful treatment of severe quetiapine intoxication with CytoSorb hemoadsorption</article-title><source>J. Clin. Pharm. Ther.</source><year>2022</year><volume>47</volume><fpage>1471</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1111/jcpt.13668</pub-id><pub-id pub-id-type="pmid">35537706</pub-id></element-citation></ref><ref id="B187-jox-14-00085"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulzen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grunder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Orlikowsky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoeltzenbein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Veselinovic</surname><given-names>T.</given-names></name></person-group><article-title>Suicide attempt during late pregnancy with quetiapine: Nonfatal outcome despite severe intoxication</article-title><source>J. Clin. Psychopharmacol.</source><year>2015</year><volume>35</volume><fpage>343</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000308</pub-id><pub-id pub-id-type="pmid">25830593</pub-id></element-citation></ref><ref id="B188-jox-14-00085"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seewoogoolam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>B.</given-names></name></person-group><article-title>Compartment syndrome of the deltoid and pectoralis major in a young man following quetiapine use</article-title><source>ANZ J. Surg.</source><year>2019</year><volume>89</volume><fpage>E335</fpage><lpage>E336</lpage><pub-id pub-id-type="doi">10.1111/ans.14468</pub-id><pub-id pub-id-type="pmid">29569829</pub-id></element-citation></ref><ref id="B189-jox-14-00085"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azzoni</surname><given-names>A.</given-names></name></person-group><article-title>Valproate and quetiapine overdose with benign outcome: A case report</article-title><source>Int. J. Psychiatry Clin. Pract.</source><year>2002</year><volume>6</volume><fpage>173</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1080/136515002760276117</pub-id><pub-id pub-id-type="pmid">24945205</pub-id></element-citation></ref><ref id="B190-jox-14-00085"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Markota</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grenc</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sinkovi&#269;</surname><given-names>A.</given-names></name></person-group><article-title>Low-dose intravenous lipid emulsion for the treatment of severe quetiapine and citalopram poisoning</article-title><source>Arh. Hig. Rada Toksikol.</source><year>2016</year><volume>67</volume><fpage>164</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1515/aiht-2016-67-2802</pub-id><pub-id pub-id-type="pmid">27331303</pub-id></element-citation></ref><ref id="B191-jox-14-00085"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plesnicar</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Lasic</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Plesnicar</surname><given-names>A.</given-names></name></person-group><article-title>Quetiapine and elevated creatine phosphokinase (CK)</article-title><source>Pharmacopsychiatry</source><year>2007</year><volume>40</volume><fpage>203</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1055/s-2007-984389</pub-id><pub-id pub-id-type="pmid">17874354</pub-id></element-citation></ref><ref id="B192-jox-14-00085"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pais</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Ayvazian</surname><given-names>P.J.</given-names></name></person-group><article-title>Priapism from quetiapine overdose: First report and proposal of mechanism</article-title><source>Urology</source><year>2001</year><volume>58</volume><fpage>462</fpage><pub-id pub-id-type="doi">10.1016/S0090-4295(01)01208-0</pub-id><pub-id pub-id-type="pmid">11549503</pub-id></element-citation></ref><ref id="B193-jox-14-00085"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nudelman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vinuela</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.I.</given-names></name></person-group><article-title>Safety in overdose of quetiapine: A case report</article-title><source>J. Clin. Psychiatry</source><year>1998</year><volume>59</volume><fpage>433</fpage><pub-id pub-id-type="doi">10.4088/JCP.v59n0806f</pub-id><pub-id pub-id-type="pmid">9721828</pub-id></element-citation></ref><ref id="B194-jox-14-00085"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahieu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vanlerberghe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Croes</surname><given-names>K.</given-names></name></person-group><article-title>Persisting Tachycardia and Late Onset Seizures in two Non Fatal Cases of Quetiapine Intoxication</article-title><source>Clin. Toxicol.</source><year>2007</year><volume>45</volume><fpage>366</fpage></element-citation></ref><ref id="B195-jox-14-00085"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Ravasia</surname><given-names>S.</given-names></name></person-group><article-title>Hypokalemia from risperidone and quetiapine overdose</article-title><source>Can. J. Psychiatry</source><year>2005</year><volume>50</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1177/070674370505000119</pub-id><pub-id pub-id-type="pmid">15754671</pub-id></element-citation></ref><ref id="B196-jox-14-00085"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cobilinschi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mirea</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andrei</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Ungureanu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cotae</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Avram</surname><given-names>O.</given-names></name><name name-style="western"><surname>Isac</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grin&#539;escu</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>&#538;incu</surname><given-names>R.</given-names></name></person-group><article-title>Biodetoxification Using Intravenous Lipid Emulsion, a Rescue Therapy in Life-Threatening Quetiapine and Venlafaxine Poisoning: A Case Report</article-title><source>Toxics</source><year>2023</year><volume>11</volume><elocation-id>917</elocation-id><pub-id pub-id-type="doi">10.3390/toxics11110917</pub-id><pub-id pub-id-type="pmid">37999569</pub-id><pub-id pub-id-type="pmcid">PMC10675033</pub-id></element-citation></ref><ref id="B197-jox-14-00085"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomruk</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Saat&#231;Io&#487;lu</surname><given-names>&#214;.</given-names></name><name name-style="western"><surname>DelIce</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alpay</surname><given-names>N.</given-names></name></person-group><article-title>Is quetiapine safe in overdose?: A case report and literature review</article-title><source>Noropsikiyatri. Ars.</source><year>2012</year><volume>49</volume><fpage>157</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.4274/npa.y5723</pub-id></element-citation></ref><ref id="B198-jox-14-00085"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stuerzebecher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groeneveld</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prasa</surname><given-names>D.</given-names></name></person-group><article-title>Different courses of quetiapine poisoning in two patients with gastric decontamination</article-title><source>Clin. Toxicol.</source><year>2020</year><volume>58</volume><fpage>620</fpage><lpage>621</lpage></element-citation></ref><ref id="B199-jox-14-00085"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sayk</surname><given-names>F.</given-names></name></person-group><article-title>Successful lipid rescue therapy in a case of severe amitriptyline/quetiapine intoxication</article-title><source>Med. Klin. Intensivmed. Notfmed</source><year>2018</year><volume>113</volume><fpage>305</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1007/s00063-017-0330-9</pub-id><pub-id pub-id-type="pmid">28785811</pub-id></element-citation></ref><ref id="B200-jox-14-00085"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajwani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pozuelo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tesar</surname><given-names>G.E.</given-names></name></person-group><article-title>Qt interval prolongation associated with quetiapine (Seroquel) overdose</article-title><source>Psychosomatics</source><year>2000</year><volume>41</volume><fpage>63</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S0033-3182(00)71175-3</pub-id><pub-id pub-id-type="pmid">10665270</pub-id></element-citation></ref><ref id="B201-jox-14-00085"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akinci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koylu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Akilli</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Cander</surname><given-names>B.</given-names></name></person-group><article-title>Rhabdomyolysis Secondary to Quetiapine and Olanzapine Intoxication Olanzapin ve Ketiapin intoksikasyonuna &#304;kincil Rabdomiyoliz</article-title><source>J. Acad. Emerg. Med. Case Reports</source><year>2014</year><volume>5</volume><fpage>87</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.5152/jaemcr.2014.72687</pub-id></element-citation></ref><ref id="B202-jox-14-00085"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>S.D.H.</given-names></name><name name-style="western"><surname>Uncles</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Willers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sable</surname><given-names>N.</given-names></name></person-group><article-title>Early treatment of a quetiapine and sertraline overdose with Intralipid<sup>&#174;</sup></article-title><source>Anaesthesia</source><year>2009</year><volume>64</volume><fpage>191</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.2008.05744.x</pub-id><pub-id pub-id-type="pmid">19143698</pub-id></element-citation></ref><ref id="B203-jox-14-00085"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Braitberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Graudins</surname><given-names>A.</given-names></name></person-group><article-title>Methylene blue used in the treatment of refractory shock resulting from drug poisoning</article-title><source>Clin. Toxicol.</source><year>2014</year><volume>52</volume><fpage>63</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.3109/15563650.2013.870343</pub-id><pub-id pub-id-type="pmid">24364507</pub-id></element-citation></ref><ref id="B204-jox-14-00085"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonati</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bernabe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cirronis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Potalivo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giovanardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schicchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crevani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scaravaggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petrolini</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Locatelli</surname><given-names>C.A.</given-names></name></person-group><article-title>Pharmacobezoar and gastric perforation in severe quetiapine intoxication: A case report</article-title><source>Clin. Toxicol.</source><year>2020</year><volume>58</volume><fpage>630</fpage></element-citation></ref><ref id="B205-jox-14-00085"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattoo</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.M.</given-names></name></person-group><article-title>Quetiapine: Relatively safe in overdose?</article-title><source>Indian. J. Psychiatry</source><year>2009</year><volume>51</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.4103/0019-5545.49456</pub-id><pub-id pub-id-type="pmid">19823635</pub-id><pub-id pub-id-type="pmcid">PMC2755169</pub-id></element-citation></ref><ref id="B206-jox-14-00085"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>J.</given-names></name></person-group><article-title>Delirium as a symptom of quetiapine poisoning</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2009</year><volume>43</volume><fpage>781</fpage><pub-id pub-id-type="doi">10.1080/00048670903001950</pub-id><pub-id pub-id-type="pmid">19629802</pub-id></element-citation></ref><ref id="B207-jox-14-00085"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silversides</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>K.C.</given-names></name></person-group><article-title>Diabetes Insipidus following Overdose of Baclofen and Quetiapine</article-title><source>Anaesth. Intensive Care</source><year>2009</year><volume>37</volume><fpage>319</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1177/0310057X0903700218</pub-id><pub-id pub-id-type="pmid">19400501</pub-id></element-citation></ref><ref id="B208-jox-14-00085"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>G.</given-names></name></person-group><article-title>Pediatric case report of quetiapine overdose and QTc prolongation</article-title><source>Ann. Clin. Psychiatry</source><year>2004</year><volume>16</volume><fpage>229</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1080/10401230490522061</pub-id><pub-id pub-id-type="pmid">15702572</pub-id></element-citation></ref><ref id="B209-jox-14-00085"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hast</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>T.B.</given-names></name></person-group><article-title>Dramatic QTc Narrowing after Intralipid Administration in Quetiapine Overdose</article-title><source>Clin. Toxicol.</source><year>2009</year><volume>47</volume><fpage>740</fpage></element-citation></ref><ref id="B210-jox-14-00085"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Presley</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Chyka</surname><given-names>P.A.</given-names></name></person-group><article-title>Intravenous Lipid Emulsion to Reverse Acute Drug Toxicity in Pediatric Patients</article-title><source>Ann. Pharmacother.</source><year>2013</year><volume>47</volume><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1345/aph.1R666</pub-id><pub-id pub-id-type="pmid">23613099</pub-id></element-citation></ref><ref id="B211-jox-14-00085"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anomelechi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hirst</surname><given-names>R.</given-names></name></person-group><article-title>Adrenaline-induced hypotension in the context of significant quetiapine overdose</article-title><source>Clin. Case Reports</source><year>2023</year><volume>11</volume><fpage>4</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/ccr3.7117</pub-id><pub-id pub-id-type="pmcid">PMC10017399</pub-id><pub-id pub-id-type="pmid">36937626</pub-id></element-citation></ref><ref id="B212-jox-14-00085"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veli</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Atanasov</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Angelov</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kanev</surname><given-names>K.P.</given-names></name></person-group><article-title>Simultaneous application of intravenous fat emulsion and charcoal hemoperfusion in quetiapine overdose case</article-title><source>Cent. Eur. J. Med.</source><year>2014</year><volume>9</volume><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.2478/s11536-013-0305-z</pub-id></element-citation></ref><ref id="B213-jox-14-00085"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cevik</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Tasyurek</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guneysel</surname><given-names>O.</given-names></name></person-group><article-title>Intralipid emulsion treatment as an antidote in lipophilic drug intoxications</article-title><source>Am. J. Emerg. Med.</source><year>2014</year><volume>32</volume><fpage>1103</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2014.05.019</pub-id><pub-id pub-id-type="pmid">24974371</pub-id></element-citation></ref><ref id="B214-jox-14-00085"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Beppu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H.</given-names></name></person-group><article-title>Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital</article-title><source>J. Pharm. Health Care Sci.</source><year>2021</year><volume>7</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s40780-021-00189-9</pub-id><pub-id pub-id-type="pmid">33531089</pub-id><pub-id pub-id-type="pmcid">PMC7856802</pub-id></element-citation></ref><ref id="B215-jox-14-00085"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arslan</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Demir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kavalci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Karakilic</surname><given-names>E.</given-names></name><name name-style="western"><surname>&#199;elikel</surname><given-names>E.</given-names></name></person-group><article-title>Treatment of Quetiapine Overdose with Intravenous Lipid Emulsion</article-title><source>Keio J. Med.</source><year>2013</year><volume>62</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2302/kjm.2012-0010-CR</pub-id><pub-id pub-id-type="pmid">23708294</pub-id></element-citation></ref><ref id="B216-jox-14-00085"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Benitez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Ternullo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Juhl</surname><given-names>G.A.</given-names></name></person-group><article-title>Acute oxcarbazepine and atomoxetine overdose with quetiapine</article-title><source>Vet. Hum. Toxicol.</source><year>2004</year><volume>46</volume><fpage>130</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">15171487</pub-id></element-citation></ref><ref id="B217-jox-14-00085"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bakhit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dufresne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sapkota</surname><given-names>D.</given-names></name><name name-style="western"><surname>Altekreti</surname><given-names>A.</given-names></name></person-group><article-title>LBBB Induced by Quetiapine Overdose: A Case Report and Literature Review</article-title><source>Am. J. Ther.</source><year>2017</year><volume>24</volume><fpage>e618</fpage><lpage>e620</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000000492</pub-id><pub-id pub-id-type="pmid">28207421</pub-id></element-citation></ref><ref id="B218-jox-14-00085"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulec</surname><given-names>H.</given-names></name><name name-style="western"><surname>Babayigit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurtay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sahap</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ulus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tutal</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Horasanli</surname><given-names>E.</given-names></name></person-group><article-title>Seizure due to multiple drugs intoxication: A case report</article-title><source>Braz. J. Anesthesiol.</source><year>2016</year><volume>66</volume><fpage>651</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1016/j.bjan.2014.02.015</pub-id><pub-id pub-id-type="pmid">27793241</pub-id></element-citation></ref><ref id="B219-jox-14-00085"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klu&#269;ka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ju&#345;en&#269;&#225;k</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kosinov&#225;</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#352;toura&#269;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kratochv&#237;l</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sedl&#225;&#269;kov&#225;</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tom&#225;&#353;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pelclov&#225;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jaband&#382;iev</surname><given-names>P.</given-names></name></person-group><article-title>Intralipid infusion in paediatric patient with quetiapine and lamotrigine intoxication</article-title><source>Monatshefte Fur Chem.</source><year>2019</year><volume>150</volume><fpage>1711</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1007/s00706-019-02423-5</pub-id></element-citation></ref><ref id="B220-jox-14-00085"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermanns Clausen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stedtler</surname><given-names>U.</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>M.</given-names></name></person-group><article-title>Quetiapine Overdose-A Case Series</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2004</year><volume>42</volume><fpage>443</fpage><lpage>444</lpage></element-citation></ref><ref id="B221-jox-14-00085"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>R.L.</given-names></name></person-group><article-title>Fatal combination of mitragynine and quetiapine&#8212;A case report with discussion of a potential herb-drug interaction</article-title><source>Forensic Sci. Med. Pathol.</source><year>2019</year><volume>15</volume><fpage>110</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s12024-018-0049-9</pub-id><pub-id pub-id-type="pmid">30498933</pub-id></element-citation></ref><ref id="B222-jox-14-00085"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hertzog</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cetran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Labadie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Braganca</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>R.</given-names></name></person-group><article-title>Delayed cardiotoxicity in venlafaxine and quetiapine overdose</article-title><source>Clin. Toxicol.</source><year>2021</year><volume>59</volume><fpage>1279</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1080/15563650.2021.1914341</pub-id><pub-id pub-id-type="pmid">33871300</pub-id></element-citation></ref><ref id="B223-jox-14-00085"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bronstein</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cantilena</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rumack</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Giffin</surname><given-names>S.L.</given-names></name></person-group><article-title>2008 Annual Report of the American Association of Poison Control Centers&#8217; National Poison Data System (NPDS): 26th Annual Report</article-title><source>Clin. Toxicol.</source><year>2009</year><volume>47</volume><fpage>911</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.3109/15563650903438566</pub-id><pub-id pub-id-type="pmid">20028214</pub-id></element-citation></ref><ref id="B224-jox-14-00085"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bronstein</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cantilena</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rumack</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Heard</surname><given-names>S.E.</given-names></name></person-group><article-title>2007 Annual Report of the American Association of Poison Control Centers&#8217; National Poison Data System (NPDS): 25th Annual Report</article-title><source>Clin. Toxicol.</source><year>2008</year><volume>46</volume><fpage>927</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1080/15563650802559632</pub-id><pub-id pub-id-type="pmid">19065310</pub-id></element-citation></ref><ref id="B225-jox-14-00085"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bronstein</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cantilena</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rumack</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Heard</surname><given-names>S.E.</given-names></name></person-group><article-title>2006 Annual Report of the American Association of Poison Control Centers&#8217; National Poison Data System (NPDS)</article-title><source>Clin. Toxicol.</source><year>2007</year><volume>45</volume><fpage>815</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1080/15563650701754763</pub-id><pub-id pub-id-type="pmid">18163234</pub-id></element-citation></ref><ref id="B226-jox-14-00085"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bronstein</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Spyker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cantilena</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rumack</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Giffin</surname><given-names>S.L.</given-names></name></person-group><article-title>2009 Annual Report of the American Association of Poison Control Centers&#8217; National Poison Data System (NPDS): 27th Annual Report</article-title><source>Clin. Toxicol.</source><year>2010</year><volume>48</volume><fpage>979</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.3109/15563650.2010.543906</pub-id><pub-id pub-id-type="pmid">21192756</pub-id></element-citation></ref><ref id="B227-jox-14-00085"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampschulte</surname><given-names>B.</given-names></name><name name-style="western"><surname>Klauwer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Faas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heckmann</surname><given-names>M.</given-names></name></person-group><article-title>Therapierefrakt&#228;re arterielle Hypotension infolge Intoxikation mit Quetiapin und Escitalopram&#8212;Therapie mit Terlipressin und Vasopressin</article-title><source>Klin. P&#228;diatrie</source><year>2010</year><volume>222</volume><fpage>GNPI_FV_64</fpage><pub-id pub-id-type="doi">10.1055/s-0030-1261399</pub-id></element-citation></ref><ref id="B228-jox-14-00085"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shafiei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>D.</given-names></name></person-group><article-title>Toxicokinetics of Quetiapine and its Active Metabolite N-desalkylquetiapine During Acute Poisoning</article-title><source>Clin. Toxicol.</source><year>2011</year><volume>49</volume><fpage>267</fpage></element-citation></ref><ref id="B229-jox-14-00085"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rauber-Luthy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kupferschmidt</surname><given-names>H.</given-names></name></person-group><article-title>Acute Intoxication with Quetiapine: A Cohort Study</article-title><source>Clin. Toxicol.</source><year>2008</year><volume>46</volume><fpage>643</fpage><pub-id pub-id-type="doi">10.1080/15563650802255033</pub-id></element-citation></ref><ref id="B230-jox-14-00085"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berling</surname><given-names>I.</given-names></name><name name-style="western"><surname>Isbister</surname><given-names>G.K.</given-names></name></person-group><article-title>Prolonged QT Risk Assessment in Antipsychotic Overdose Using the QT Nomogram</article-title><source>Ann. Emerg. Med.</source><year>2015</year><volume>66</volume><fpage>154</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2014.12.005</pub-id><pub-id pub-id-type="pmid">25639523</pub-id></element-citation></ref><ref id="B231-jox-14-00085"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalifa</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Elmansy</surname><given-names>A.</given-names></name></person-group><article-title>Predictors for prolonged qt intervals in acute antipsychotic poisoned patients</article-title><source>Toxicol. Res.</source><year>2024</year><volume>13</volume><fpage>tfae038</fpage><pub-id pub-id-type="doi">10.1093/toxres/tfae038</pub-id><pub-id pub-id-type="pmcid">PMC10944555</pub-id><pub-id pub-id-type="pmid">38500514</pub-id></element-citation></ref><ref id="B232-jox-14-00085"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Whyte</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>A.H.</given-names></name></person-group><article-title>Cardiotoxicity more common in thioridazine overdose than with other neuroleptics</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>1995</year><volume>33</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.3109/15563659509017984</pub-id><pub-id pub-id-type="pmid">7760442</pub-id></element-citation></ref><ref id="B233-jox-14-00085"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>M.M.</given-names></name></person-group><article-title>Toxicology Investigators Consortium (ToxIC). Evolving trends of pharmaceutical poisonings associated with QRS complex prolongation</article-title><source>Clin. Toxicol.</source><year>2024</year><volume>62</volume><fpage>574</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1080/15563650.2024.2390138</pub-id><pub-id pub-id-type="pmcid">PMC11421585</pub-id><pub-id pub-id-type="pmid">39194962</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jox-14-00085-f001" orientation="portrait"><label>Figure 1</label><caption><p>Observed dose-normalised quetiapine concentration vs. time (decontamination/no decontamination). Dashed lines are fitted monoexponential curves.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jox-14-00085-g001.jpg"/></fig><fig position="float" id="jox-14-00085-f002" orientation="portrait"><label>Figure 2</label><caption><p>Observed dose-normalised quetiapine concentration versus time (immediate-release/extended-release formulation). Dashed lines are fitted monoexponential curves.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jox-14-00085-g002.jpg"/></fig><fig position="float" id="jox-14-00085-f003" orientation="portrait"><label>Figure 3</label><caption><p>Lowest Glasgow Coma Scale score&#8212;case distribution by dose and peak concentration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jox-14-00085-g003.jpg"/></fig><fig position="float" id="jox-14-00085-f004" orientation="portrait"><label>Figure 4</label><caption><p>Toxicodynamic parameters vs. ingested quetiapine dose boxplot. Circles denote outlyers by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jox-14-00085-g004.jpg"/></fig><fig position="float" id="jox-14-00085-f005" orientation="portrait"><label>Figure 5</label><caption><p>Toxicodynamic parameters vs. quetiapine peak serum concentration boxplot. Circles denote outlyers by Tukey&#8217;s test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jox-14-00085-g005.jpg"/></fig><table-wrap position="float" id="jox-14-00085-t001" orientation="portrait"><object-id pub-id-type="pii">jox-14-00085-t001_Table 1</object-id><label>Table 1</label><caption><p>Pharmacokinetic and toxicokinetic parameters of quetiapine [<xref rid="B2-jox-14-00085" ref-type="bibr">2</xref>,<xref rid="B10-jox-14-00085" ref-type="bibr">10</xref>,<xref rid="B19-jox-14-00085" ref-type="bibr">19</xref>,<xref rid="B27-jox-14-00085" ref-type="bibr">27</xref>,<xref rid="B28-jox-14-00085" ref-type="bibr">28</xref>,<xref rid="B32-jox-14-00085" ref-type="bibr">32</xref>,<xref rid="B33-jox-14-00085" ref-type="bibr">33</xref>,<xref rid="B34-jox-14-00085" ref-type="bibr">34</xref>,<xref rid="B35-jox-14-00085" ref-type="bibr">35</xref>,<xref rid="B36-jox-14-00085" ref-type="bibr">36</xref>,<xref rid="B37-jox-14-00085" ref-type="bibr">37</xref>,<xref rid="B39-jox-14-00085" ref-type="bibr">39</xref>,<xref rid="B40-jox-14-00085" ref-type="bibr">40</xref>,<xref rid="B41-jox-14-00085" ref-type="bibr">41</xref>,<xref rid="B42-jox-14-00085" ref-type="bibr">42</xref>,<xref rid="B43-jox-14-00085" ref-type="bibr">43</xref>,<xref rid="B44-jox-14-00085" ref-type="bibr">44</xref>,<xref rid="B45-jox-14-00085" ref-type="bibr">45</xref>,<xref rid="B46-jox-14-00085" ref-type="bibr">46</xref>,<xref rid="B47-jox-14-00085" ref-type="bibr">47</xref>,<xref rid="B48-jox-14-00085" ref-type="bibr">48</xref>,<xref rid="B49-jox-14-00085" ref-type="bibr">49</xref>,<xref rid="B50-jox-14-00085" ref-type="bibr">50</xref>,<xref rid="B51-jox-14-00085" ref-type="bibr">51</xref>,<xref rid="B52-jox-14-00085" ref-type="bibr">52</xref>,<xref rid="B53-jox-14-00085" ref-type="bibr">53</xref>,<xref rid="B54-jox-14-00085" ref-type="bibr">54</xref>,<xref rid="B55-jox-14-00085" ref-type="bibr">55</xref>,<xref rid="B56-jox-14-00085" ref-type="bibr">56</xref>,<xref rid="B57-jox-14-00085" ref-type="bibr">57</xref>,<xref rid="B58-jox-14-00085" ref-type="bibr">58</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pharmacokinetic Profile</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Toxicokinetic Profile</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XR</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comments</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">bioavailability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70% </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">equivalent to IR </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">variable and lower than in therapeutic doses;<break/>e.g., 40% after 10 g IR </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no data&#8212;lower than in therapeutic doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">k<sub>a</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.77&#8211;2.5/h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1&#8211;0.19/h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3/h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no data&#8212;lower than IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gastric emptying may be delayed </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V<sub>D</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">380&#8211;710 L, <break/>or 8&#8211;14 L/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">equivalent to IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">589 L </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">equivalent to IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">t<sub>max</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;2 h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8211;6 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">variable, 1&#8211;20 h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">variable, up to <break/>56 h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c<sub>max</sub> may not have been reached at the reported time</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c<sub>max</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dose-dependent, with linear pharmacokinetics </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dose-dependent, with linear pharmacokinetics, lower (~67%) than IR </td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">conflicting data on dose&#8211;concentration relationship; lower than anticipated from pharmacokinetic models </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2nd peak may be present</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">t<sub>1/2</sub>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3&#8211;7 h </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">equivalent to IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">variable, 5&#8211;22 h; <break/>may be biphasic, with phase 1 t<sub>1/2</sub> 5&#8211;10 h (&lt;12&#8211;48 h post-ingestion, and phase 2 t<sub>1/2</sub> 22&#8211;77 h (&gt;12&#8211;48 h post-ingestion) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">variable; may be prolonged&#8212;up to 31 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55&#8211;138 L/h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">equivalent to IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73 L/h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">declines with age </td></tr></tbody></table><table-wrap-foot><fn><p>c<sub>max</sub>: peak concentration; Cl: apparent clearance; IR: immediate-release; k<sub>a</sub>: absorption rate constant; t<sub>max</sub>: time to peak concentration; t<sub>1/2</sub>: half-life; V<sub>D</sub>: volume of distribution; XR: extended-release.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jox-14-00085-t002" orientation="portrait"><object-id pub-id-type="pii">jox-14-00085-t002_Table 2</object-id><label>Table 2</label><caption><p>Patient demographics, clinical presentation and treatment strategies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reported QTP Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reported QTP Concentration</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No. of Cases * <break/>(N = 134)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% (Valid)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No. of Cases * <break/>(N = 118)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No. of Cases * <break/>(N = 65)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">age&#8212;median (IQR)</td><td align="left" valign="middle" rowspan="1" colspan="1">years</td><td colspan="2" align="center" valign="middle" rowspan="1">32.5 (24.75&#8211;44)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">sex</td><td align="left" valign="middle" rowspan="1" colspan="1">male/female</td><td align="center" valign="middle" rowspan="1" colspan="1">55/76</td><td align="center" valign="middle" rowspan="1" colspan="1">(41.9/58.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">49/66</td><td align="center" valign="middle" rowspan="1" colspan="1">23/41</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">coingestants</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">58/76</td><td align="center" valign="middle" rowspan="1" colspan="1">(43.3/56.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">49/69</td><td align="center" valign="middle" rowspan="1" colspan="1">28/37</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">dosage form</td><td align="left" valign="middle" rowspan="1" colspan="1">IR/XR</td><td align="center" valign="middle" rowspan="1" colspan="1">53/30</td><td align="center" valign="middle" rowspan="1" colspan="1">(63.9/36.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">49/28</td><td align="center" valign="middle" rowspan="1" colspan="1">31/13</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hospital length of stay&#8212;median (IQR)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">days</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">4 (2&#8211;7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">Clinical events, signs and symptoms:</td></tr><tr><td rowspan="4" align="left" valign="middle" colspan="1">lowest GCS score level</td><td align="left" valign="middle" rowspan="1" colspan="1">1 (death)</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">12.8</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2 (GCS 3&#8211;8)</td><td align="center" valign="middle" rowspan="1" colspan="1">78</td><td align="center" valign="middle" rowspan="1" colspan="1">58.6</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3 (GCS 9&#8211;14)</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">24.1</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4 (GCS 15)</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">tachycardia</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">93/21</td><td align="center" valign="middle" rowspan="1" colspan="1">(81.6/18.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">81/19</td><td align="center" valign="middle" rowspan="1" colspan="1">47/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hypotension</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">65/44</td><td align="center" valign="middle" rowspan="1" colspan="1">(59.6/40.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">54/41</td><td align="center" valign="middle" rowspan="1" colspan="1">34/21</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QT<sub>c</sub> prolongation</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">44/67</td><td align="center" valign="middle" rowspan="1" colspan="1">(39.6/60.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">40/61</td><td align="center" valign="middle" rowspan="1" colspan="1">21/31</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QRS prolongation</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">24/90</td><td align="center" valign="middle" rowspan="1" colspan="1">(21.1/78.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">19/83</td><td align="center" valign="middle" rowspan="1" colspan="1">15/39</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">seizures</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">34/89</td><td align="center" valign="middle" rowspan="1" colspan="1">(27.6/72.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">27/82</td><td align="center" valign="middle" rowspan="1" colspan="1">21/37</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rhabdomyolysis</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">12/90</td><td align="center" valign="middle" rowspan="1" colspan="1">(11.8/88.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">12/80</td><td align="center" valign="middle" rowspan="1" colspan="1">4/40</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">agitation</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">32/87</td><td align="center" valign="middle" rowspan="1" colspan="1">(26.9/73.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">28/78</td><td align="center" valign="middle" rowspan="1" colspan="1">21/35</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">delirium</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">17/92</td><td align="center" valign="middle" rowspan="1" colspan="1">(15.6/84.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">13/83</td><td align="center" valign="middle" rowspan="1" colspan="1">12/38</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hypokalaemia</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">17/66</td><td align="center" valign="middle" rowspan="1" colspan="1">(24.1/75.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">15/59</td><td align="center" valign="middle" rowspan="1" colspan="1">7/35</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">acidosis</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">19/79</td><td align="center" valign="middle" rowspan="1" colspan="1">(19.4/80.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">16/72</td><td align="center" valign="middle" rowspan="1" colspan="1">13/36</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">arrhythmia</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">14/104</td><td align="center" valign="middle" rowspan="1" colspan="1">(11.9/88.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">10/98</td><td align="center" valign="middle" rowspan="1" colspan="1">8/47</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">heart block</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">21/97</td><td align="center" valign="middle" rowspan="1" colspan="1">(17.8/82.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">16/92</td><td align="center" valign="middle" rowspan="1" colspan="1">14/42</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hyperglycaemia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11.4/88.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/32</td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1">Treatment strategies:</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">decontamination (any)</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">58/58</td><td align="center" valign="middle" rowspan="1" colspan="1">(50.0/50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">55/51</td><td align="center" valign="middle" rowspan="1" colspan="1">27/26</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICU admission</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">66/20</td><td align="center" valign="middle" rowspan="1" colspan="1">(76.7/23.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">61/20</td><td align="center" valign="middle" rowspan="1" colspan="1">32/6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICU length of stay&#8212;median (IQR)</td><td align="left" valign="middle" rowspan="1" colspan="1">days</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1&#8211;4)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">intubation</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">72/55</td><td align="center" valign="middle" rowspan="1" colspan="1">(56.7/43.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">64/29</td><td align="center" valign="middle" rowspan="1" colspan="1">34/27</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">physostigmine</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">14/111</td><td align="center" valign="middle" rowspan="1" colspan="1">(11.2/88.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">12/100</td><td align="center" valign="middle" rowspan="1" colspan="1">8/51</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">vasopressors</td><td align="left" valign="middle" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" rowspan="1" colspan="1">35/87</td><td align="center" valign="middle" rowspan="1" colspan="1">(28.7/71.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">29/79</td><td align="center" valign="middle" rowspan="1" colspan="1">21/38</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">intralipid emulsion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes/no</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18/107</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(14.4/85.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/52</td></tr></tbody></table><table-wrap-foot><fn><p>GCS: Glasgow Coma Scale; ICU: Intensive Care Unit; QTP: quetiapine; * For each parameter, cases with missing data are not presented.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jox-14-00085-t003" orientation="portrait"><object-id pub-id-type="pii">jox-14-00085-t003_Table 3</object-id><label>Table 3</label><caption><p>Lowest Glasgow Coma Scale (&#8804;8 or &#8805;9) vs. quetiapine dose and peak concentration&#8212;logistic regression results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">OR</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">95% C.I. for OR</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sig.</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Omnibus Test&#8212;Model (Sig.)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Hosmer and Lemeshow Test (Sig.)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td rowspan="2" colspan="2" align="left" valign="middle" style="border-bottom:solid thin">lowest GCS score vs. dose <break/>(continuous)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dose (g)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.118</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.049</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.192</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.149</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">constant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.711</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.334</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="4" colspan="2" align="left" valign="middle" style="border-bottom:solid thin">lowest GCS score vs. dose <break/>(categorical; cat. 1: dose &#8804; 3 g; <break/>cat. 2: 3 g &lt;dose &#8804; 8 g; <break/>cat. 3: dose &gt; 8 g)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dose &#8804; 3 g (ref.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 g &lt;dose &#8804; 8 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.950</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.586</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.328</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dose &gt; 8 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.955</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.221</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.899</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">constant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.471</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.079</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" colspan="2" align="left" valign="middle" style="border-bottom:solid thin">lowest GCS score vs. <break/>peak concentration (continuous)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peak c (mg/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.319</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.707</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.974</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">constant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.975</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" colspan="2" align="left" valign="middle" style="border-bottom:solid thin">lowest GCS score vs. peak concentration (categorical; <break/>cat. 1: peak c &#8804; 5 mg/L; <break/>cat. 2: peak c &gt; 5 mg/L)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peak c &gt; 5 mg/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.709</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114.685</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> *</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">constant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.786</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>C.I.: confidence interval; GCS: Glascow Coma Scale; OR: odds ratio; * Hosmer and Lemeshow test not calculated for dichotomous independent variable.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>